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ABSTRACT 
Inflammatory bowel disease (IBD) is a common ailment affecting people of all ages. Even 
though the pathogenesis of IBD has not been fully elucidated, there is evidence that it 
involves interactions between genetic susceptibility, aberrant activation of the immune 
system, and the environment. Inflammation of the colon (colitis) results in pain, diarrhea, 
hemorrhage, and weight loss. Within the colon, the family of mucins (MUC) and trefoil 
factors (TFF) facilitate mucosal protection. Recent studies found that probiotic 
administration could influence the colonic mucin layer. Additionally, food components may 
affect gut microflora or have influence on the mucin barrier. Our aims were to explore the 
role of probiotic administration in modulating MUC and TFF gene expression in the dextran 
sodium sulfate (DSS) induced colitis mouse model, and to examine interactions with casein, 
whey, or soy protein diets. C57BL/6 mice were assigned to three diet groups. Diets were 
formulated to substitute casein, whey or soy protein on an equivalent basis. On day 6, each 
diet group was divided into 2 groups, with or without Lactobacillus rhamnosus GG (LGG) 
added daily to the diet. Starting on day 12 the mice were given 2% DSS in drinking water for 
4 days and then euthanized 1 day later. A casein diet group with neither LGG nor DSS 
treatment served as a control. Colon tissues and cecal samples were collected and analyzed 
by quantitative RT-PCR. LGG-specific gene expression was found in cecum contents of all 
mice given LGG but none of the untreated mice. Mice fed whey protein had significantly 
higher LGG quantity compared to mice fed casein diets. Colonic MUC1 and TFF3 gene 
expression were increased by DSS treatment. In mice fed soy protein, induction of MUC1 
and TFF3 expression after DSS was suppressed. Mice fed whey protein had intermediate 
viii 
 
 
 
TFF3 gene expression compared to the other diet groups. There was no overall probiotic 
effect on any of the parameters. As a marker of inflammation, TNF-α gene expression was 
increased after DSS treatment. Mice fed soy protein, however, had suppressed TNF-α 
expression compared to the other treatment groups, which was consistent with the colon 
length change and colonic inflammation score. In conclusion, soy protein suppressed the 
DSS-induced inflammatory stimulation of MUC, TFF and TNF-α gene expression 
independently of the probiotic. Whey protein may act as a prebiotic in the colon to increase 
microbial survival, but these factors failed to prevent the inflammatory response. Future 
studies are needed to identify the bioactive components in the soy protein that modulate the 
barrier function in the colon and have protective effects against colitis.
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CHAPTER 1 
LITERATURE REVIEW 
1. Physiological and cellular characterization of the colon mucosa 
The colon is the distal region of the digestive system in vertebrates. The major functions of 
the colon are to absorb water and electrolytes, absorb vitamins synthesized by the bacteria in 
the lumen, and compact and store fecal matter until it can be expelled. The colon wall 
consists of four layers, from outer surface inward, including adventitia, muscularis externa, 
submucosa and mucosa. The adventitia is the outmost connective tissue covering the colon. It 
consists of several layers of epithelia. The muscularis externa consists of an inner circular 
layer and a longitudinal outer muscular layer, which are responsible for gut motility. The 
submucosa is the layer of dense irregular connective tissue with blood vessels, lymphatics, 
and nerves between the smooth muscle and the mucosa. The most inner layer of the 
gastrointestinal (GI) tract is the mucosa, which surrounds the lumen (1). This layer comes in 
direct contact with food, and is responsible for absorption of nutrients, secretion of mucus, 
and the mucosal barrier it forms is an important component of the immune system. 
Lymphoid follicles consisting of  B lymphocytes, T lymphocytes, dendritic cells and 
macrophages are present in colonic mucosa and may extend through the muscularis mucosa 
into the submucosa  (2). Going from inside the lumen radially outwards, the mucosa can be 
divided into epithelium, lamina propria, and muscularis mucosa.  
The epithelium is composed of absorptive epithelium, goblet, and endocrine cells. The 
epithelium contains no enzyme-secreting cells. Instead, it consists mainly of goblet cells that 
secrete mucus. There are some endocrine cells in the colon secreting small amounts of 
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somatostatin that regulates digestion. Paneth cells are not normally present in the mucosa of 
the colon. The presence of Paneth cells more distally indicates metaplastic changes seen in 
chronic infection such as in patients with ulcerative colitis (3). Paneth cells secrete 
antimicrobial substances such as defenses, lysozyme, and phospholipase A2 indicating a role 
for Paneth cells in host defense (4). The lamina propria is a thin layer of loose connective 
tissue with capillaries and lymphoid cells which lies under the epithelium. It contains several 
cell types, including plasma cells, T cells, NK cells, eosinophils, mast cells, and macrophages, 
most of which are responsible for local, immunologically mediated host defense against 
harmful agents from the lumen. In inflammatory conditions, there is inflammatory cell 
infiltration by neutrophils, macrophages and lymphocytes. The muscularis mucosa is the thin 
layer of smooth muscle separating the lamina propria from the submucosa (1).  
Crypts of Lieberkuhn are straight tubular glands that are found in the epithelial lining of the 
colonic mucosa. There are millions of crypts in a normal colon. Crypts contain about 2000 
cells, which are maintained by stem cells (undifferentiated progenitor cells) located near or at 
the bottom of each crypt (5).  Large numbers of mucus-secreting goblet cells fill the crypts of 
the colon. Branching of the crypts, increasing of plasma cells and lymphocytes between the 
bases of the crypts and the muscularis mucosa, and neutrophil infiltration in crypt epithelium 
are histopathological characteristics of chronic inflammation and inflammatory bowel 
disease (IBD) (6). 
Aberrant crypt foci (ACF) are clusters of abnormal tube-like glands in the lining of the colon 
and rectum, which can be found before the early stage of colorectal polyps. The appearance 
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of ACF is one of the earliest changes that might lead to colon cancer. They can be detected 
under a microscope with methylene blue staining (7). 
There is a large population of microbes in the gut. It is reported that the bacteria density in 
the human colon may be as abundant as 10
10
-10
12
 colony-forming units per gram of colonic 
contents (8). The commensal bacteria collectively make up the intestinal microbiota. The 
human host and its microbiota constitute a complex ecosystem whose equilibrium serves as a 
remarkable example of reciprocal adaptation (9). Most microbes belong to the genera 
Bacteroides, Clostridium, Fusobacterium, Eubacterium, Ruminococcus, Peptococcus, 
Peptostreptococcus, and Bifidobacterium. Other genera, such as Escherichia and 
Lactobacillus, are present to a lesser extent (10). The commensal bacteria are essential to 
human health. They form resistance to pathogen colonization via producing antimicrobial 
substances, changing luminal pH and directly competing against pathogens for nutrients, 
thereby obstructing and inhibiting pathogen invasion (11, 12). Commensal bacteria also 
facilitate the development and optimal functioning of the host immune system (13).  
The mucous layer is the first defense barrier between bacteria and the epithelial cells in the 
gut (14-18). The mucous layer lining the surface epithelium of the intestine acts as a lubricant 
and protective physical barrier between the mucosal surface and the luminal contents. 
Particles, bacteria, and viruses are trapped in the mucous layer and eliminated by the 
peristaltic movement of the gut. In the presence of this barrier, pathogens and antigens cannot 
gain access to the underlying epithelium and are blocked from invading the body (2). The 
mucous layer consists of mucus glycoprotein (mucins) and trefoil factors that are secreted by 
goblet cells. Mucin is a family of high molecular weight, heavily glycosylated proteins 
4 
 
 
 
produced by goblet cells. The mucins can form gels. Trefoil factors are stable secretory 
proteins by goblet cells expressed in GI mucosa, which may protect the mucosa from insults, 
stabilize the mucus layer and affect healing of the epithelium (19, 20).  
Mucins that form the protective barrier to the mucosa are divided to three main types, 
including secretory (gel forming) mucins, membrane bound mucins, and a group of 
nonclassified mucins. The secretory mucins include MUC2, MUC5AC, MUC5B, and MUC6. 
Secretory mucins are produced in goblet cells of the GI tract. Membrane mucins are MUC1, 
MUC3A, MUC3B, MUC4, MUC11, MUC12 and MUC17 (21). The membrane bound 
mucins are produced in nonspecialized serous or epithelial cells, for instance, the enterocytes 
(22). MUC1, MUC2, MUC3 and MUC4 are the major mucins expressed in the large intestine 
in humans. In particular, MUC2 is the main secreted colonic mucin (23). The mucin genes in 
mice are similar to those found in human. It has been found in BALB/c mice that MUC3 is 
the most commonly expressed mucin in the large intestine, followed by MUC2. In contrast, 
MUC1 and MUC4 are poorly expressed (24). The mucin barrier is critical in limiting contact 
between bacteria and epithelial cells. Dysfunction of this protective barrier may lead to IBD. 
For example, MUC2 knockout mice spontaneously developed colitis, indicating that MUC2 
is important for colonic protection (25).  
The trefoil factor (TFF) peptides TFF1, TFF2, and TFF3 are expressed by mucus-secreting 
cells, mainly in the GI tract, with specific cellular localization of each peptide. TFF1 is 
expressed by surface epithelial cells of the stomach, and TFF2 in mucous neck cells, pyloric 
glands, and Brunner’s glands, whereas TFF3 is mainly located in goblet cells of the small 
and large intestine (26). TFF3 is a key peptide in mucosal protection and repair. It cooperates 
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at the epithelial barrier with mucin glycoproteins to enhance the protective barrier. Knockout 
of the TFF3 gene led to an increased susceptibility to dextran sulfate sodium (DSS)-induced 
colitis, and intraluminal infusion of TFF3 rescued the TFF3 defect through coordinated 
promotion of intestinal cell migration and inhibition of intestinal cell apoptosis (27). On the 
other hand, overproduction of TFF3 is found in a variety of GI inflammatory conditions, such 
as necrotizing enterocolitis and IBD, which indicates that dysregulation of TFF3 occurs 
during inflammatory conditions (28).  
 
2. Overview of inflammatory bowel diseases  
Inflammatory bowel diseases are a group of chronic inflammatory conditions in the colon 
and small intestine.  According to data published in 2004, there were as many as 1.4 million 
persons in the United States and 2.2 million persons in Europe suffering from IBD (29). The 
incidence of IBD has increased during recent decades, not only in Western countries, but also 
in some regions where IBD had been less common such as Japan (30). 
IBD includes the two major diseases, Crohn’s disease and ulcerative colitis (31). There are 
several differences between these conditions. The main difference is the location of the 
inflammatory changes. Crohn's disease can affect any part of the alimentary tract, from 
mouth to anus, even though most of the cases start in the terminal ileum. In contrast, 
ulcerative colitis is restricted to the colon and the rectum. Crohn’s disease typically involves 
transmural inflammation, and the lesions may be patchy and segmental, whereas ulcerative 
colitis develops diffuse mucosal inflammation. The histological feature of Crohn’s disease is 
6 
 
 
 
the aggregation of macrophages which usually form non-caseating granulomas, while 
ulcerative colitis is distinguish by the neutrophils aggregation within lamina propria and 
crypts, where they form microabscesses. Depletion of goblet cell mucin is also common in 
ulcerative colitis (32). The major symptoms of IBD include diarrhea, hemorrhage, abdominal 
pain, and weight loss, which subsequently affect the quality of life for patients (33).  There is 
evidence that patients with ulcerative colitis and Crohn's disease had a higher risk of 
developing intestinal cancer, even though the mechanisms have not been fully understood 
(34-37). O’Connor et al. (38) explored these mechanisms, and stated that IBD patients were 
exposed to constant activation of nuclear factor-kappaB (NF-κB) and cyclooxygenase-2/ 
prostaglandin pathways, release of proinflammatory cytokines, and increased local levels of 
reactive oxygen and nitrogen species. Collectively, the chronic presence of these 
inflammatory signals can have carcinogenic effects through the following major processes: 1) 
by enhancing oxidative stress, which promotes DNA mutagenesis thereafter contributing to 
tumor initiation; 2) by activating prosurvival and antiapoptotic pathways in epithelial cells, 
thus contributing to tumor promotion; and 3) by creating an environment that supports 
sustained growth, angiogenesis, migration, and invasion of tumor cells, thereby supporting 
tumor progression and metastasis (38, 39). Due to the rising incidence and significant 
association with human health, IBD has been extensively studied during the last several 
decades. 
 
3. Etiology of IBD  
Even though the pathogenesis of IBD has not been fully understood, there is evidence that it 
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involves interactions between genetic susceptibility, immune system, and the environment, 
most notably the colonic microflora (40).  
The importance of genetic factors in IBD was originally suggested by epidemiological 
studies showing familial aggregation of IBD and by twin studies. The NOD2 (CARD15) 
gene, which is located on chromosome 16, was the first susceptibility gene characterized in 
Crohn's disease (41-45). In 1996, Hugot et al. (45) performed a genome-wide search on two 
consecutive and independent panels of families with multiple Crohn's disease patients and 
found that a susceptibility locus for Crohn's disease, named IBD1, was located near the 
pericentromeric region of chromosome 16. Further study was conducted to identify the 
specific gene in this region. Subsequently, the NOD2 gene has been sequenced in 50 Crohn's 
disease patients (41). There were 13 polymorphisms identified. Two amino acid changes 
involving single nucleotide polymorphisms (Arg702Trp and Gly908Arg) and one frameshift 
mutation (3020insC) that leads to a premature stop codon was also linked to Crohn's disease. 
Bacterial peptidoglycan may activate NOD2 and thereafter activates the NF-κB and mitogen-
activated protein (MAP) kinase signaling pathways, which results in the production of 
proinflammatory cytokines (46, 47). Recently, the use of genome-wide association studies 
(GWAS) has provided new insights into primary pathogenetic mechanisms. Besides NOD2, 
there are more genes identified, including NOD1, DLG5, TLR4, OCTN1 and OCTN2. The 
GWAS also facilitated the recognition of additional genes such as ATG16L1, IL23R, IRGM 
and PTGER4 (48, 49). For instance, ATG16L1 is the autophagy gene that was found to 
regulate secretion of interleukin-1β, interleukin-18 and suppress intestinal inflammation. 
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Mice lacking ATG16L1 in hematopoietic cells were extremely susceptible to DSS induced 
acute colitis (50).  
Innate immune response is the first line of defense against microbial infection and provides a 
rapid response to pathogens. Recent evidence supports that innate immune responses play an 
essential role in initiating the inflammatory cascade and help to shape the subsequent and 
characteristic pathological adaptive immune responses associated with IBD (51). Several 
types of components from bacteria and viruses such as lipopolysacharide (52), peptidoglycan, 
flagellin, and lipoproteins, can be detected by pattern recognition receptors (PRRs) of the 
host. Interaction of these ligands with their cognate PRRs activate intracellular signaling 
cascades that induce the expression of a variety of overlapping and unique genes involved in 
inflammatory and immune responses (52). The toll-like receptor (TLR) and nucleotide-
binding oligomerization domain (NOD) receptor families of PRRs are found to play 
important roles in mucosal homeostasis and relate to the pathogenesis of IBD (53). It has 
been described that the expression of TLR3 and TLR4 were modulated in IBD. TLR3 was 
downregulated in intestinal epithelial cells during active Crohn’s disease, whereas TLR4 was 
increased in both Crohn’s disease and ulcerative colitis (54). The activation of the NOD2 by 
bacterial peptidoglycan leads to the production of proinflammatory cytokines as mentioned 
above (46, 47).  
Several environmental risk factors for IBD have been investigated, including smoking, 
appendectomy, oral contraceptives, diet, breastfeeding, infections, antibiotics, and childhood 
hygiene (55). Migrant studies have clearly demonstrated that lifestyle and environmental 
influences are more important to IBD etiology than regional, ethnic, and racial differences 
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because individuals moving from low-occurrence areas to high-occurrence areas show an 
increased incidence of disease (29). For instance, a 3-year prospective study of ulcerative 
colitis in a city in the United Kingdom found that extensive colitis was more frequent in the 
second-generation migrants than in the first. The incidence was comparable to the European 
community (56). It was found that consumption of fast foods conferred a high risk for IBD 
(57), while raw vegetable and fruits, whole grain, and coffee were suggested to have 
protective effects (57, 58).  
Bacteria have long been considered essential to the development of IBD (59). It was 
observed that in the different parts of the intestine, the locations with more bacteria were 
those where there were higher incidence of inflammation (60). An increasing number of 
clinical studies in patients with IBD and laboratory studies in animal models point to the 
important role of the microbiota in the initiation and development of inflammation (60, 61). 
Giaffer et al. (62) accessed the microbiota of IBD patients and observed an increase of 
Escherichia coli and a decrease of Bifidobacteria in patients with Crohn’s disease. In another 
similar study, the fecal microbiota of patients with IBD was specified via fluorescent in situ 
hybridization adapted to flow cytometry. It was found that there was a significantly higher 
percentage of bacteria that could not be recognized by the probes in patients with IBD 
compared to healthy subjects, which indicated there were more unusual bacteria in the fecal 
samples of IBD patients. They also observed a decrease of Clostridium, a commensal 
bacteria genera, in IBD patients (61). The necessity of bacteria in the establishment of 
experimental colitis models also supports the importance of bacteria in IBD etiology. Early in 
1998, Sellon et al. (59) demonstrated that resident enteric bacteria were necessary for 
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developing spontaneous colitis. Transgenic mice kept under germ free conditions did not 
develop colitis until they were administered bacterial strains. Consistently, it was shown that 
if the animals were treated with antibiotic first, experimental colitis could not be induced (63). 
Bacteria which can adhere to and invade the intestinal mucosa may be especially critical, for 
instance, E. coli (64). E. coli are the major facultative anaerobic, Gram-negative species of 
the normal intestinal microbiota. In normal human intestine, commensal E. coli cannot 
adhere to the apical face of intestinal epithelial cells. However, the pathogenic E. coli, which 
hereditably  obtain virulence genes encoding adhesive factors, are able to adhere to the apical 
face of intestinal epithelial cells and cause pathogenic reactions (65). For instance, the 
enterotoxigenic E. coli (65), enteropathogenic E. coli (66) and enterohemorrhagic E. coli (67) 
were found to have the ability to attach to the epithelium and cause gastroenteritis. E. coli 
strains are suspected to be associated with the pathogenesis of Crohn’s disease. A microflora 
examination found that E. coli were found abnormally predominant in early as well as 
chronic lesions of Crohn’s disease patients. They consisted 50% to 100% of the total amount 
of aerobes and anaerobes (68).   
 
4. IBD animal models: classification, DSS model  
Dependable, reproducible, and clinically relevant experimental colitis models are needed to 
study the molecular events related to the disease progression and to explore the prevention 
strategies for IBD and subsequent colon cancer (69). There are several categories of 
experimental colitis models, including genetically engineered models, spontaneous colitis 
models, inducible colitis models, and adoptive transfer models (70). Genetically engineered 
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models consist of gene knockout mouse models and transgenic mouse/rat models. Mice with 
knockout of several genes, such as interleukin-2 (IL-2) (71), IL-10 (72), STAT3 (73), tumor 
necrosis factor (TNF)-3′ untranslated region (74), intestinal trefoil factor (27), and T cell 
receptor (75), have been shown to develop colitis when harboring a conventional microbiota. 
IL-17 transgenic mice (70), STAT4 transgenic mice (76), HLA B27 transgenic rats (77) are 
transgenic models that have been reported. Models of spontaneous colitis include 
C3H/HeJBir mice (78) and SAMP/Yit mice (79). Several chemicals have been utilized to 
induce colitis in rodents, such oxazolone (80), DSS (81), 2,4,6-trinitrobenzene sulfonic acid 
(TNBS) (82), and carrageenan (83). CD4+/CD45RB
high
 T cells transfer colitis (84) and colitis 
induced by transfer of hsp60-specific CD8 T-cells (85) are the two adoptive transfer models 
that have been established. 
 The DSS-induced colitis model originally reported by Okayasu et al. (81) has been widely 
used to investigate colitis. This model is easy to develop, and the characteristics of this model 
are close to those of ulcerative patients. In addition, DSS can be used to induce both acute 
colitis and chronic inflammation (86). DSS interferes with the intestinal epithelial barrier first, 
which is a physical barrier against excessive entry of bacteria from gut lumen into the lamina 
propria, and then stimulates local inflammation as the secondary phenomenon (87). Acute 
colitis could be induced by 4-day treatment of 5% DSS (88), while a cycle of 5% DSS 
administration, followed by a 2-5 week recovery period resulted in chronic colitis in Swiss 
Webster mice, which was characterized by slower epithelial regeneration and an adaptive 
immune response characterized by both Th1 as well as Th2 cytokine profiles, including  IFN-
γ and IL-4, respectively (86). In general, DSS treatment causes weight loss, diarrhea with 
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blood and/or mucus, shortening of the colon, erosion of the mucosal epithelium, and acute 
neutrophilic infiltration all of which are similar to the clinical and histological features of 
ulcerative colitis (81, 87).  
Widely used inflammatory markers for DSS induced colitis include myeloperoxidase (MPO) 
activity, proinflammatory cytokines such as IL-1β, IL-6, IL-12, TNF-α, IFN-γ, and 
chemokines KC and MIP-2 (87). These markers are usually measured in the colon samples or 
the plasma by several techniques such as western blotting, enzyme-linked immunosorbent 
assay (ELISA), or polymerase chain reaction (PCR). The transcription factor NF-κB signal 
pathway is an important pathway associated with colitis. Experimental colitis models are 
characterized by NF-κB activation and relative proinflammatory cytokines upregulation (87, 
89, 90). For instance, in the study by Reed et al. (89), rats were treated with 5% DSS in 
drinking water and sacrificed daily for 6 days. NF-κB activation increased on day 1 and again 
on days 4 through 6. The colonic mRNA levels for IL-1β and TNF-α rose significantly 
between 2 and 4 days. Increased iNOS mRNA levels, MPO activity, and mucosal damage 
occurred on day 6. In another study, C57BL/6 mice were treated with 3.5% DSS for various 
times. The proinflammatory cytokines of colonic mucosa such as IL-1β, IL-6, IL-12, TNF-α, 
and IFN-γ were increased after DSS treatment (87). The histological examination has been 
widely used as another inflammatory parameter. The histological scores are usually based on 
the severity of mucosal epithelial damage, glandular alterations, and the character of lamina 
propria cellular infiltration. Mucosa height, mucosa erosion, inflammatory score, edema 
score, and inflammatory cell infiltration are evaluated in the tissue sections stained with 
hematoxylin and eosin (91). 
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5. MUC genes and DSS induced colitis  
MUC genes are altered in IBD. In a study that examined colon biopsies for MUC1 expression 
by immunochemistry using MUC1-specific antibody and analyzed MUC1 serum 
concentrations by ELISA in IBD patients, overexpression of MUC1 was found (92). The 
increased MUC1 levels were correlated with clinical disease severity. This study suggested 
that MUC1  could be used as an inflammatory biomarker  and assisted monitoring the disease 
activity of IBD (92).  
Alterations of MUC gene expression are also observed in DSS-induced colitis models (24, 
93, 94). Hoebler et al. (24) treated BALB/c mice with 1% DSS for 5 days to induce acute 
inflammation, followed by 0.5% DSS for 28 days to induce chronic inflammation. It was 
found that MUC2 gene expression was not modified by DSS treatment, while MUC3-specific 
mRNA expression was increased after acute colitis only in the cecum and distal colon. 
MUC1 and MUC4 gene expression were enhanced significantly by colitis. This suggested 
that mucin production helps to maintain and to recover the protective capacities of the mucus 
layer, which were changed during experimental colitis (24). In another study, Sprague-
Dawley rats were administered 5% DSS for 9 days followed by 2% DSS for 18 days to 
induce chronic colitis (93). It was observed that DSS-treated rats had higher mRNA levels of 
colonic MUC2 and MUC3 compared with pair-fed controls (93). In the study by Renes et al 
(94), Wistar rats were given 7% DSS in the drinking water for 7 days, followed by a 3 week 
recovery period. Immunohistochemistry observation showed that MUC2 was produced by 
goblet cells in the proximal and distal colon from crypt base to the surface epithelium. 
Alterations in the numbers and localization of goblet cells were observed during and after 
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DSS treatment. On day 2, MUC2 positive goblets accumulated in the surface epithelium 
along the length of the colon. As DSS administration proceeded (day 5 and 7), there were 
more MUC2 positive goblet cells located along the surface epithelium. Biochemical analysis 
of MUC2 protein levels showed a progressive increase in MUC2 in the proximal colon 
during DSS treatment, and MUC2 levels rose four-fold over that of the control levels on day 
7. Thereafter, the MUC2 levels decreased but were still higher compared to the control levels. 
In the distal colon, MUC2 tended to decrease during the active inflammatory phase, and 
returned to control levels during the regenerative phase (94).  
In brief, MUC gene expression was altered in IBD patients and experimental colitis models. 
The MUC genes might be used as targets of IBD prevention and therapy.  
 
6. TFF genes and DSS induced colitis 
Trefoil factor play an important role in mucosal protection in the intestine. There is 
increasing evidence indicating the association of TFF dysregulation with IBD. A clinical 
study found that serum concentrations of TFF1, TFF2, and TFF3 were significantly increased 
in IBD patients compared with healthy controls (95). The presence of increased TFF3 levels 
correlated with clinical and biochemical parameters of disease activity in ulcerative colitis 
patients. After medical therapy, TFF levels tended to reduce, which was consistent with 
clinical and biochemical remission (95).   
Upregulation of TFF3 peptides and/or TFF3-specific mRNA in colonic samples was 
observed in DSS-induced colitis of mice or rats (94, 96, 97). In the study by Renes et al. (94), 
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Wistar rats were given 7% DSS in the drinking water for 7 days, followed by a 3 week 
recovery period. Immunohistochemistry observation showed that, TFF3 was expressed in the 
upper crypts in the proximal colon and upper two-thirds of the crypts in the distal colon. On 
day 2, TFF3 positive goblet cells accumulated in the surface epithelium in the whole colon. 
As DSS administration proceeded (day 5 and 7), there were more TFF3 positive goblet cells 
found in the surface epithelium. Protein dot blotting showed an increase of TFF3 peptide in 
the colon samples (94). Consistently, it was observed in the DSS-induced colitis using a 
BALB/c mouse model that both TFF3 peptide and mRNA were increased significantly (24, 
98). As opposed to the finding in IBD patients, TFF1 and TFF2 mRNA were not changed 
significantly in DSS-induced colitis of mice, which indicates that DSS induced colitis might 
have an acute pathology, while IBD lesions exhibit a more chronic nature (98).  
How TFF3 mediates its protective and healing effects on the epithelium is not fully 
understood. It has been proposed that these effects are mediated by cellular responses which 
might involve receptor-ligand interactions. In vitro experiments demonstrated that TFF3 
enhanced the expression of decay-accelerating factor (DAF), which is another important 
mucosal defensive protein interrupting the complement activation pathways, and thus 
protects the tissues from autologous complement-mediated injury (99, 100). Andoh et al. 
(100) found that TFF3 induced an increase in DAF protein and mRNA expression in human 
and rat intestinal epithelial cells in normal conditions. It has been shown that TFF3 blocks 
complement C3 deposition. In HT-29 cells, TFF3 increased DAF mRNA stability and 
enhanced DAF promoter activity via NF-κB motif and induced activation of NF-κB-DNA 
binding activity. In summary, TFF3 promoted protection of epithelial cells from 
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complement-mediated damage via up-regulation of DAF expression  contributing to a robust 
mucosal defense (100).  
Due to the association between TFF dysregulation and IBD, the functions of TFF genes in 
colitis should be further investigated. Animal studies can be conducted to explore how the 
modulation of TFF genes would affect the incidence and development of colitis.   
 
7. TNF-α as an inflammatory marker in DSS induced colitis 
It is well documented that TNF-α is an inflammatory marker associated with DSS-induced 
colitis (87, 89, 90). It is a 17 kDa polypeptide produced by many cell types including 
activated monocytes and macrophages, neutrophils, T and B lymphocytes, mast cells, 
basophils, eosinophils, NK cells, endothelial cells, smooth muscle cells, and astrocytes (101). 
When macrophages or other cells are stimulated with LPS in the cell wall of Gram-negative 
bacteria, TNF-α is secreted as one of the earliest proinflammatory cytokines and enter the 
systematic circulation (102). It functions as a chemoattractant for neutrophils, and facilitates 
them to stick to the endothelial cells for migration. It enhances phagocytosis and stimulates 
production of IL-1 and prostaglandin E2 in macrophages. In the hypothalamus, as an 
endogenous pyrogen, it increases the thermoregulatory set-point in the hypothalamus and 
causes fever (103, 104). In the liver, TNF-α stimulates the acute phase response and increases 
protein synthesis, leading to an increase in C-reactive protein and a number of other 
mediators. The synthesis of TNF-α is induced by the activation of the transcription factor 
NF-κB. After activation, NF-κB translocates to the nucleus and induces gene transcription of 
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several cytokines, such as IL-1β, IL-2, IL-6, IL-8, IL-12, TNF-α, IFN-γ, and COX-2 (89, 
102). 
Reed et al. (89) investigated the temporal relationship between NF-κB activation and the 
expression of proinflammatory cytokines and other peptides in the rat DSS colitis model. 
Rats were given 5% DSS in their water and sacrificed daily for 6 days. NF-κB activation, 
TNF-α and other cytokines protein levels and gene expression were measured by 
electrophoretic mobility shift assay and relative RT-PCR, respectively. It was observed that 
NF-κB activation increased on day 1 of the DSS administration and again 3 days later. The 
level of TNF-α-specific mRNA rose significantly on day 5.  
An study by Yan et al. (87) observed the dynamic changes of inflammatory parameters 
including TNF-α in the DSS-induced colitis mouse model. They found that the production of 
TNF-α increased progressively during the DSS treatment, and reached the maximum amount 
on the 5
th
 day. After withdrawing the DSS, TNF-α maintained a high level in the colon 
tissues  until 2 weeks after the treatment, when the animals were sacrificed (87).  
Egger et al. (105) demonstrated that the induction of TNF-α in acute murine DSS colitis was 
dose-dependent. In their study, four groups of BALB/c mice were given different 
concentrations of DSS (0, 2.5, 5 and 7.5%) in drinking water for 7 days ad libitum. Cytokine-
specific mRNA levels in the colon tissues were determined by competitive quantitative RT-
PCR. It was observed that gene expression for TNF-α was progressively upregulated with 
increasing dosage of DSS (105).   
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8. Probiotics and barrier function 
Probiotics were first described by Lilly and Stillwell in 1965 (106). They are selective  
nonpathogenic living microorganisms, including some commensal bacterial species, that 
protect host health and may help prevent or/and treat some diseases (106). The World Health 
Organization (FAO/WHO, 2002) has defined probiotics as “living microorganisms which, 
when consumed in adequate amounts as part of food, confer a health benefit on the host.” 
Certain Lactobacillus, Bifidobacterium, and Saccharomyces species are commonly utilized 
probiotics. Lactobacillus and Bifidobacterium, especially Lactobacillus rhamnosus, L. 
acidophilus, Bifidobacterium longum, and B. bifidum are the most commercially used species 
of lactic acid bacteria in products such as probiotic yogurts and probiotic pills (31, 107). 
Among these lactic acid bacteria, L. rhamnosus has been thoroughly investigated and has 
been shown to survive gastric, bile and intestinal secretion, adhere to the intestinal epithelium 
and colonize the colon after oral consumption in a 12-day human study (108). Probiotics 
have been found to enhance the health state of the GI tract and have been applied to prevent 
and treat several intestinal inflammatory disorders, such as necrotizing enterocolitis and IBD 
(31, 109-112). There are several studies about the beneficial effects of probiotics on IBD. 
Gupta et al. (113) observed that L. rhamnosus GG (LGG) was beneficial in children with 
Crohn’s disease. In this study, four children with mildly to moderately active Crohn’s disease 
were given 10
10 
colony-forming units of LGG in enterocoated tablets twice daily for 6 
months. The results showed that LGG decreased the disease activity 1 week after the 
initiation of the administration and the protective effect was maintained during the study 
period. The double sugar permeability test suggested that the probiotic administration 
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improved intestinal permeability, which was consistent with the changes of the disease 
activity. Consistent with these observations, a meta-analysis study showed that LGG was 
effective in treating acute diarrhea in children (114). An animal study found that LGG 
administration decreased MPO activity in the TNBS model of colitis (115). Three distinct 
cellular and molecular mechanisms for probiotic regulation of IBD were demonstrated by 
Vanderpool et al. (31) in a recent review paper: i) Probiotics produce antibacterial substances 
and compete with pathogens and toxins for adherence to the intestinal epithelium and thus 
block pathogenic bacterial effects; ii) Probiotics regulate immune responses by modulating 
innate immunity and pathogen-induced inflammation via toll-like receptors mediated 
signaling pathways; iii) Probiotics regulate intestinal epithelial homeostasis by enhancing 
intestinal epithelium survival, promoting barrier function and stimulating protective 
responses.  
Intestinal mucins and TFF are components of a complex regulatory network that acts as the 
first line of host defense against enteric pathogens. Abnormal regulation of this network 
might lead to inflammatory conditions of the intestine. There is evidence supporting that 
probiotics have certain effects on the modulation of intestinal barrier function. In healthy 
Wistar rats, it was observed that oral administration of the probiotics mixture VSL#3 
containing 3 Bifidobacterium strains (B. breve, B. longum, and B. infantis), 4 Lactobacillus 
strains (L. acidophilus, L. plantarum, L. paracasei, and L. bulgaricus) and Streptococcus 
thermophilus on a daily basis for 7 days increased basal luminal mucin content by 60%. The 
isolated rat colonic loops that exposed to the probiotic formula had increased amount of 
mucin secretion and a higher gene expression of MUC2. Meanwhile, MUC1 and MUC3 gene 
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expression were slightly increased (116). Consistently, another study showed that LGG 
enhanced gastric mucosal integrity in Sprague-Dawley rats by upregulating MUC6-specific 
mRNA expression and increasing the mucus layer thickness (117). On the other hand, under 
inflammatory conditions, probiotic administration could normalize the abnormal stimulation 
of MUC- or TFF-specific mRNA expression. Khailova et al. (111) found that B. bifidum 
normalized the increased levels of MUC3 and TFF3 in a rat model of necrotizing 
enterocolitis. Another study also showed that oral administration of LGG reduced mucin 
gene expressions in the DSS induced colitis mouse model (118).    
In summary, use of probiotics can inhibit the growth of pathogens, modulate the immune 
response, and enhance the barrier function of the gut, thereby promoting gut health. Thus, 
probiotic is beneficial in preventing and/or treating intestinal inflammation.  
 
9. Dairy proteins and barrier function 
Casein was originally defined in 1956 as those phosphoproteins that precipitate from raw 
skim milk by acidification to pH 4.6 at 20°C (119). According to the homology of their 
primary structures, casein was divided into four families, including αS1-casein, αS2-casein, β-
casein and κ-casein (119). Casein accounts for nearly 80% of protein in cow’s milk (120). It 
is used as the basic protein source in the AIN 93 rodent diet formulation (121).  
Whey is obtained from the cheese-making process. It is the liquid remaining after milk has 
been curdled and strained to remove the casein (120). It contains water, proteins, lactose, 
vitamins, minerals, and traces of fat. Whey protein represents 20% of the total protein 
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content of cow’s milk. It is used commercially as a nutritional supplement. Whey protein 
contains 5 major proteins, including 35% β-lactoglobulin, 12% α-lactalbumin, 12% 
glycomacropeptide, 12% proteose peptone, and 8% immunoglobulins, which together make 
up over 80% of the total whey protein. It also contains 5% serum albumin, 1% lactoferrin, 
0.5% lactoperoxidase, and some minor proteins (120).  
Whey protein contains bioactive components such as glycomacropeptide and lactoferrin, 
which may be beneficial in preventing colitis (122, 123). Glycomacropeptide and lactoferrin 
also have prebiotic properties that have been shown to support the growth of bifidobacteria 
and lactobacilli and thereafter promote gut health (124). An in vivo study found that adding 
16% cheese whey protein in the diet significantly increased the amount of lactobacilli and 
bifidobacteria in fecal samples of the rats after 3 weeks (125). In addition, whey protein is a 
rich source of threonine, cysteine, serine and a certain amount of proline, which are the major 
amino acid constituents of GI secretory mucins (126).  
Faure et al. (127) found that the supplementation of threonine, cysteine, serine and a certain 
amount of proline increased the production of mucins and ameliorated histological changes 
in DSS-induced colitis in rats. From 8 days before to 28 days after induction of colitis, male 
Sprague-Dawley rats were fed a control diet or diets supplemented with 2 different doses of 
an amino acid mixture containing L-threonine, L-serine, L-proline, and L-cysteine. It was 
found that the higher dose of amino acids increased the number of MUC2-containing goblet 
cells in the surface epithelium of the ulcerated area, enhanced mucin production in the colon 
by 95% and improved histological scores. Recently, the protective effects of whey protein 
against DSS-induced colitis were explored with respect to how whey protein changed the 
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microbiota and mucin (125). During this study, colitis was induced by 3% DSS treatment for 
7 days. Rats were divided into three diet groups containing casein, cheese whey protein, or 
casein supplemented with threonine and cysteine. Whey protein reduced DSS-induced 
mucosal gene expression of inflammatory markers such as IL-1β, calprotectin, and inducible 
nitric oxide synthase and relieved the clinical signs of diarrhea and hematochezia. Fecal 
mucin secretion was increased by whey protein without altering MUC2 gene expression. In 
addition, whey protein increased the number of lactobacilli and bifidobacteria in fecal 
samples. The rats fed the casein supplemented with threonine and cysteine diet exhibited 
similar effects. This study suggested that whey protein provided protection against colitis via 
enhancing mucin synthesis and stimulating the survival of the probiotics (125).  
   
10. Soy protein and barrier function 
Soybean has been considered a good source of protein throughout history. There is 
approximately 50% protein in the soybean. Soybean protein provides all of the essential 
amino acids for human nutrition, thus, it is called a “complete protein”. Edible soy protein is 
derived from defatted soy flour and has a high solubility in water (128). Several studies have 
shown that soy protein isolate with isoflavones is protective against colon cancer, although 
the mechanisms are not well defined (129, 130). Vis et al. (131) observed that soy protein 
influenced several colon cancer risk parameters such as cell proliferation, fecal fat, fecal bile 
acid, and alkaline phosphatase in a rat model. Cai et al. (132) examined the effects of soy 
protein on the intestinal barrier function. Acute enteritis was induced by radiation in Sprague-
Dawley rats. Then the rats were assigned to two groups fed either soy protein or casein 
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protein. Bacterial translocation rates, lipopolysacharide (LPS) concentrations in serum, and 
mucosal thickness were analyzed. It was found that soy protein decreased bacterial 
translocation, LPS levels in the circulation, and improved mucosa repair suggesting that 
soybean protein alleviated radiation damage and protected the bowel barrier function in rats.  
Many of the health benefits of soy protein attribute to its isoflavones, which are a family of 
phytoestrogens found mainly in soybeans. Soy contains many types of isoflavones, but the 
most beneficial are genistein and daidzein (133). In vitro studies found that genistein 
inhibited the proliferation of colon cancer cells and promoted the apoptosis of these cells 
(134, 135). An animal study investigated the effect of genistein on IBD with the TNBS 
induced chronic colitis rat model (136). They found that 14-day oral administration of 100 
mg/kg genistein reduced colonic expression of COX-2 mRNA and protein and decreased 
MPO activity compared to the control group. These results suggested that oral administration 
of genistein exerted anti-inflammatory effects in experimental colitis animals (136).   
Recently, a bioactive peptide named lunasin in soy protein has been isolated. Lunasin is 
composed of 43 amino acids residues and a predicted helix with structural homology to a 
conserved region of chromatin binding protein (137). Lunasin has been found to be 
bioavailable in humans. A human study showed that amino acid sequences from lunasin were 
present in plasma samples after soy intake for 30 min and 1 h, whereas no peptides from 
lunasin were detected in plasma samples without soy intake (138).     
It has been found that lunasin had anti-inflammation effects via inhibiting the NF-κB 
pathway in the macrophages (139, 140). In vitro study by De Mejia et al. (139) found that 
lunasin and lunasin-like peptide purified from defatted soybean flour inhibited the pro-
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inflammatory markers such as IL-1β, IL-6, NF-κB transactivation, COX-2 expression, and 
nitric oxide synthase expression in RAW 264.7 macrophages. Another in vitro experiment by 
Hernández-Ledesma et al. (140) used LPS-stimulated RAW 264.7 macrophages to study the 
anti-inflammatory effects of lunasin. They observed that lunasin reduced the production of 
reactive oxygen species (ROS) by LPS-induced macrophages in a significant dose-dependent 
manner and inhibited the release of pro-inflammatory cytokines TNF-α and IL-6. These 
results supported the conclusion that lunasin had anti-inflammation properties and may 
explain some of the GI health benefits of soy protein.   
It has also been proposed that soy protein may influence the growth of probiotics. Soy 
products have been given much attention lately as dairy replacers and carriers for probiotics, 
without the lactose intolerance factors. For instance, soy yogurt is made by fermenting 
soymilk with probiotics, mainly L. bulgaricus and S. thermophilus (141, 142). Tsinberg et al. 
(143) studied the growth features of 3 strains of Bifidobacterium and 3 strains of 
Lactobacillus in hydrolysate-milk or hydrolysate-soybean media (HMM and HSM, 
respectively) comparatively. The bacterial cells were investigated morphometrically with 
atomic force microscopy. They found that HSM promoted a higher growth rate of the strains 
than HMM, and this effect was more obvious for the bifidobacteria as compared to the 
lactobacilli (143). However, a later study that determined the utilization of lactose and 
production of organic acid in reconstituted skim milk (RSM) and RSM supplemented with 
soy protein isolate (RSMS) had different findings (144). Six probiotic organisms were grown 
in the two media, including 4 strains of Lactobacillus and 2 strains of Bifidobacteria. The 
results were that the viable microbial populations in RSMS were lower than those in RSM 
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due to lower pH of the former, even though all 6 probiotic organisms produced significantly 
more acetic acid in RSMS than RSM. This study suggested that the addition of soy protein 
enhanced lactose utilization and acetic acid production but did not increase the growth of 
probiotic microorganisms (144).  
 
11. Hypothesis 
Intestinal mucins and TFF compose a network that acts as the first line of host defense 
against enteric pathogens. Dysregulation of MUC and TFF genes were found in IBD patients 
and DSS-induced colitis models. Previous studies supported the concept that probiotics can 
modulate the mucin secretion and mucin gene expression in healthy subjects or subjects with 
active inflammatory conditions. Whey protein and soy protein have the potential to stimulate 
the growth of probiotic organisms and/or regulate the MUC and TFF gene expression in vitro 
and in vivo. Hence, we hypothesized that probiotic administration would enhance colonic 
barrier function via modulating mucin and TFF3 gene expression in the DSS-induced colitis 
mouse model. Casein, whey, or soy diets would differentially affect the colonic barrier 
function directly by modulating mucin gene expression and TFF3 and/or by enhancing the 
growth of the probiotic organism. 
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Abstract  
The incidence of inflammatory bowel diseases (IBD) has increased during recent decades. 
Within the colon, the family of mucins and trefoil factors (TFF) facilitate mucosal protection. 
Probiotic administration influences the intestinal mucin layer. Additionally, food components 
may affect gut microflora or have direct effects on the mucin barrier. Our objective was to 
determine if diet and/or administration of Lactobacillus rhamnosus GG (LGG) would 
attenuate dextran sulfate sodium (DSS)-induced colitis by altering expression of the MUC 
and TFF genes. C57BL/6 mice were fed diets containing casein, soy, or whey protein along 
with or without LGG for 12 days. Seven days after starting LGG diets, the mice were given 
2% DSS for 4 days. One day after the DSS treatment the colonic and cecal tissues and fecal 
samples were collected and analyzed by quantitative RT-PCR for MUC, TFF genes and LGG 
specific gene. Whey protein significantly increased cecal LGG content compared to the other 
diets. MUC1 gene expression was induced by DSS and diets containing soy protein 
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dramatically suppressed the induction. Colonic TFF3-specific mRNA was upregulated by 
DSS and decreased by soy and whey protein. Soy protein also reduced the inflammatory 
scores, TNF-α expression and prevented colon shortening. There was no overall effect of 
LGG on these parameters. In conclusion, soy protein suppressed the DSS-induced 
inflammatory stimulation of MUC, TFF and TNF-α gene expression independently of the 
probiotic. Whey protein may act as prebiotic to increase microbial survival, but failed to 
prevent the inflammatory response. Hence diet but not probiotic affected the colonic mucosal 
barrier in DSS-treated mice.  
Key words: IBD, MUC, TFF, probiotic, soy protein, whey protein 
Introduction  
Inflammatory bowel diseases (IBD) are a group of chronic inflammatory conditions of the  
small and large intestine, and includes  two major diseases, Crohn’s disease and ulcerative 
colitis (31). In 2004,  as many as 1.4 million persons in the United States and 2.2 million 
persons in Europe suffered from IBD (29). The incidence of IBD has continued to increase 
during recent decades, not only in the Western countries, but also in some regions where IBD 
had been less common such as Japan (30). There is evidence that patients with ulcerative 
colitis and Crohn's disease have a higher risk of developing intestinal cancer, even though the 
mechanisms have not been fully understood (34-37). O’Connor et al. (38) demonstrated that 
IBD patients were exposed to constant activation of nuclear factor-kappaB (NF-κB) and 
cyclooxygenase-2/prostaglandin pathways, release of proinflammatory cytokines, and 
increased local levels of reactive oxygen and nitrogen species. Collectively, the chronic 
presence of these inflammatory signals may have carcinogenic effects (38).  
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Even though the pathogenesis of IBD is not fully elucidated, there is evidence that it involves 
interactions between genetic susceptibility, aberrant activation of the immune system, and the 
environment (40). A number of environmental risk factors for IBD have been explored, 
including smoking, appendectomy, oral contraceptives, diet, breastfeeding, infections, 
antibiotics, and degree of childhood hygiene (55). Migrant studies have clearly demonstrated 
that lifestyle and environmental influences are more important to IBD etiology than regional, 
ethnic and racial differences as evidenced by the increased risk of IBD for individuals 
moving from low-occurrence areas to high-occurrence areas (29).  
The DSS-induced colitis model originally reported by Okayasu et al. (81) has been used to 
investigate colitis. This model is easy to develop, and the characteristics are very similar to 
those of ulcerative colitis patients. Inflammatory parameters for DSS-induced colitis include 
increased myeloperoxidase (MPO) activity, proinflammatory cytokines such as IL-1β, IL-6, 
TNF-α, IFN-γ, and histological scores based on the severity of mucosal epithelial damage, 
glandular alterations, and the character of lamina propria cellular infiltration (87, 91). 
The mucous layer overlying colonic epithelial cells consists of mucus glycoproteins (mucins 
or MUC) and trefoil factors (TFF) that are secreted by goblet cells is a first defense barrier 
between bacteria and the mucosal cells in the gut (14, 15, 17, 18). In the presence of a 
functional barrier, pathogens and antigens cannot gain access to the underlying epithelium 
and are thereby blocked from invading the body (2). 
The MUC1, MUC2, MUC3 and MUC4 glycoproteins are the major mucins expressed in the 
large intestine in humans. In particular, MUC2 is the main secreted colonic mucin (23). Loss 
of this protective barrier may predispose to IBD. For instance, MUC2 knockout mice 
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spontaneously developed colitis, indicating that the presences of MUC2 was important for 
colonic protection (25). Overexpression of MUC1-specific mRNA was found in IBD patients 
(92) and MUC1 and MUC4 gene expression were enhanced significantly in the mouse model 
of DSS-induced colitis (24).  
The TFF1, TFF2, and TFF3 proteins are produced by mucus-secreting cells, mainly in the 
gastrointestinal (GI) tract, with specific cellular localization of each peptide. TFF3 is mainly 
located in goblet cells of the small and large intestine (26). TFF3 is a key peptide in mucosal 
protection and repair. It interacts with mucin glycoproteins to enhance the protective 
epithelial barrier function. Knockout of the TFF3 gene led to an increased susceptibility to 
colitis after exposure to DSS, and intraluminal infusion of TFF3 rescued the TFF3 deficiency 
through coordinated promotion of intestinal cell migration and inhibition of intestinal cell 
apoptosis (27). In contrast, overproduction of TFF3 is found in a variety of GI inflammatory 
conditions, such as necrotizing enterocolitis and IBD, which suggests that upregulation of 
TFF3-specific mRNA is a feature of GI inflammation  (28).  
Probiotics have certain effects on the modulation of intestinal barrier function. Gupta et al. 
(113) observed that L. rhamnosus GG (LGG) was beneficial in children with Crohn’s disease. 
In healthy Wistar rats,  oral administration of the probiotics mixture VSL#3 on a daily basis 
for 7 days increased the amount of mucin secretion and a higher gene expression of MUC1, 
MUC2, and MUC3 in the colon (116). However, under inflammatory conditions, probiotic 
administration normalized the abnormal regulation of MUC- or TFF-specific mRNA (111, 
145).  
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Whey protein contains bioactive components such as glycomacropeptide and lactoferrin, 
which have prebiotic properties to support the growth of bifidobacteria and lactobacilli and 
subsequently promote gut health (124). Soy products have been given much attention lately 
as dairy replacers and carriers for probiotics, without the lactose intolerance factors (142). It 
has been suggested that soy protein may promote the growth of Bifidobacteria and 
Lactobacillus species (143). In addition, an animal study demonstrated the ability of soy 
proteins to enhance intestinal barrier function (132).  
Based on the interactions between the mucus barrier, use of probiotics, and different protein 
supplements, we hypothesized that probiotic administration would enhance colonic barrier 
function via modulating MUC and TFF gene expression in the murine model of DSS induced 
colitis. Furthermore, we hypothesize that casein, whey, or soy protein supplemented diets 
would differentially affect the colonic barrier function by modulating MUC gene expression 
and TFF and/or by enhancing the growth of the probiotic organism(s).  
Materials and Methods 
Animals and diet 
All animal protocols were approved by the Iowa State University Animal Care and Use 
Committee. Female C57BL/6NHsd Helicobacter negative mice, aged 6-7 weeks (Harlan, 
Haslett, MI) were housed individually, exposed to 12 h light and dark cycles and given free 
access to tap water. Casein and whey protein isolates will be purchased from commercial 
sources and the soy protein, depleted of isoflavones will be obtained from the Archer Daniels 
Midland Company. Powdered diets were prepared using a modification to the standard AIN-
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93G formula (121) as shown in Table 1 and were stored frozen. Immediately prior to feeding 
each day, the diets were quantitatively mixed with water to form a thick paste. This was done 
to assure survivability of the probiotic.  Body weight and food intake were monitored daily.  
 
Table 1  Diet compositions    
          
  Source casein
1
 soy whey 
  g/kg 
Casein MP Biomedicals 200 0 0 
Whey protein Leprino Foods, Inc. 0 0 250 
Soy protein concentrate Archer Daniels Midland 0 275 0 
DL-methionine
2
 MP Biomedicals 3 3 3 
Sucrose General Stores 100 100 100 
Corn Starch MP Biomedicals 397.5 322.5 347.5 
Dyetrose Dyets, Inc.  132 132 132 
Cellulose
3
 General Stores 50 50 50 
Safflower oil
4
 MP Biomedicals 20 20 20 
Corn oil
4
 General Stores 50 50 50 
AIN-93VX vitamin mix  MP Biomedicals 10 10 10 
AIN-93G mineral mix  MP Biomedicals 35 35 35 
Choline bitartrate MP Biomedicals 2.5 2.5 2.5 
Energy content, kcal/kg  3868 3746 3933 
Nitrogen content, g/kg  30.4 30.4 30.4 
 
1
same as for AIN-93G with the exceptions noted in superscripts below and that tert-butyl- 
hydroquinone was omitted (diets stored at -15ºC).       
2
used instead of L-cystine       
3
used instead of Solka-Floc® fiber       
4
used instead of 70 g/kg soybean oil   
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Bacterial growth conditions 
Lactobacillus rhamnosus GG ATCC 53103 was acquired from the American Type Culture 
Collection (ATCC, Manassas, VA, USA) as a lyophilized sample and maintained as frozen 
stocks at −75°C in deMan-Rogosa-Sharpe medium (MRS, #288130, BD Diagnostic Systems, 
Sparks, MD) containing 20% (v/v) glycerol. Working cultures of L. rhamnosus ATCC 53103 
were maintained as slants on MRS at 4°C, and sub-cultured in MRS broth at 37°C under 
stationary culture conditions. During each day of the feeding trial, 100 mL of the bacterial 
cell suspension containing 3 x 10
10
 CFU/mL was prepared by inoculating 100 mL of MRS in 
a 250 mL Erlenmeyer flask and incubating overnight at 37°C under stationary conditions.  
The culture broth was centrifuged (12,000 x g, at 4°C for 10 min) and cell pellet was washed 
twice with phosphate buffered saline (PBS) to remove traces of nutrient medium. One gram 
of bacterial cell pellet was re-suspended aseptically into 5 mL of PBS. From this bacterial 
suspension, 100 µL (20 mg of bacterial pellet) was pipetted onto the surface of each 
moistened diet placed in a plastic disposable 10 mL beaker and then fed the mice. Cell counts 
of the bacterial suspension were taken half-way through the bacterial feeding period and on 
the last day of the bacterial treatment showed 6 x 10
11
 CFU/mL and 3 x 10
11
 CFU/mL, 
respectively. 
Treatments 
Mice were acclimated for 5 d to meal-fed training with casein, soy, or whey protein diets. On 
day 6, each diet group was divided into two groups placed in separate rooms: one for those 
given L. rhamnosus GG (LGG) and the other room for a saline control added daily to the 
surface of diets freshly moistened by mixing 0.4 g, 1.1 g, or 0.4 g tap water per gram of diet 
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to casein, soy, or whey powdered diets, respectively for 12 d. Diets were given during the 
first 5-6 h of the dark cycle. To prevent bacterial contamination of the control group, lab 
coats, gloves, and animal caretakers were dedicated to each room. Seven days after starting 
the LGG diets, mice were given drinking water without or with 2% dextran sodium sulfate 
(DSS, #160110, MP Biomedicals, Solon, OH) that was prepared fresh daily. After the 4-day 
DSS treatment period, the DSS solution was replaced with water for 24 h and then mice were 
euthanized by carbon dioxide asphyxiation. The colon and cecum were removed and the 
colon length was measured. The colon was flushed with PBS, weighed and prepared for 
histology or RNA extraction and stored at -80ºC. The cecum was weighed and the cecal 
contents were removed and both were stored at -80ºC for RNA or DNA extraction. 
Histological staining and goblet cell counts 
Half of the longitudinal distal colon was fixed in 10% neutral buffered formalin overnight. 
Specimens were placed in 70% ethanol until embedded in paraffin, sectioned at 7µm and 
stained with alcian blue as previously described (146). Briefly, deparaffinized and hydrated 
slides were soaked in 1% alcian blue with 3% acetic acid for 30 min then rinsed in 3% acetic 
acid, washed in slow-running water and counterstained for 5 min in Kernechtrot stain (0.1% 
nuclear fast red in 5% aluminum sulfate) before dehydrating and mounting with acrytol 
mounting media (Surgipath, Richmond, IL). To determine the number of goblet cells per 
colonic crypt, the numbers of alcian blue-stained cells of 4-6 crypts for each of 2-4 regions of 
the colon slide were counted under light microscopy at 400x magnification and the results 
were expressed as the mean value per crypt. 
Colon histological measurements and colitis scoring 
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Colon tissue showed the typical 3-layer morphology with the crypt layer (from the luminal 
end of the crypt to the surface of the thin basal muscle layer) bordered on the basal part with 
a thin muscle layer then a “space” sometimes filled with immune cells defined as the 
inflammatory layer (from the surface of the thin basal muscle layer under the crypts to the 
surface of the lower thicker muscle layer) and lastly, a thicker muscle layer. The thicknesses 
of these layers in 2-4 regions of the colon slide for each mouse were measured at 400x 
magnification, using AxioVision 4.6.3 software and expressed as the mean ± SE per 
experimental group. 
Colitis was scored over the whole colon slide by an observer blinded to the treatment groups 
according the morphological criteria described by Suzuki et al. (147): 0 = normal colon 
mucosa; 1 = shortening the basal 1/3 of crypts with slight inflammation and edema in the 
lamina propria; 2 = loss of the basal two-thirds of the crypts with moderate inflammation in 
the lamina propria; 3 = loss of all the crypts with severe inflammation in the lamina propria, 
but with the surface epithelium still remaining; 4 = a loss of all the crypts and surface 
epithelium with severe inflammation in the mucosa, muscularis propria and submucosa.  
RNA isolation 
Distal pieces (0.5 cm) of colon and cecum were placed in 1 mL RNALater® (Applied 
Biosystems, Foster City, CA) at 4ºC overnight, removed from RNALater® and stored at -
80ºC. Total RNA was isolated using the Trizol method with RNAse-free reagents. Briefly,  
tissue was homogenized in 1 mL Trizol (Invitrogen, Carlsbad, CA) with an Omni 
homogenizer (#TH115, Omni  International, Kennesaw, GA), mixed with 0.2 mL chloroform, 
centrifuged 12,000 x g for 15 min and the RNA was precipitated from the aqueous layer 
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using 0.5 mL isopropanol followed by washing twice with 1 mL iced 75% ethanol. The 
resulting RNA was dissolved in 50 µL nuclease-free water, heated for 5 min to 65ºC, treated 
with a TURBO DNA free kit (# AM1907, Applied Biosystems, Foster City, CA) according 
to the manufacturer’s instructions, diluted 1:5 with nuclease-free water and RNaseOUT® 
(Invitrogen, Carlsbad, CA) and stored at 4ºC. The concentration of RNA was measured with 
a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
DNA extraction from cecal contents 
DNA was extracted from cecal contents using the UltraClean® Fecal DNA Isolation Kit 
(#12811-100, MoBio Laboratories, Inc. Carlsbad, CA) with the following modifications to 
the manufacturer’s instructions. Before step 5, proteinase K (MoBio #1222-2) was added and 
heated to 55ºC for 1 hour and, in step 12, Solution CB3 (MoBio #12240-50-3) was used 
instead of solution S3. The concentration of extracted DNA (stored at 4ºC) was measured 
with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). 
Quantitative real-time polymerase chain reaction 
Primers mixed with TaqMan® probes in a kit for real-time reverse transcriptase quantitative 
polymerase chain reaction (RT-qPCR) for the following mouse genes were obtained 
commercially (TaqMan® Gene Assay, Applied Biosystems, Foster City, CA): trefoil factor-2 
(TFF2, # Mm00447491_m1), intestinal trefoil factor-3 (TFF3, # Mm00495590_m1), 
transmembrane mucin-1 (Muc1, # Mm00449604_m1), mucin-2 (Muc2, # Mm00458299_m1), 
intestinal mucin-3 (Muc3, # Mm01207064_m1), mucin-4 (Muc4, # Mm00466886_m1), 
keratin 19 (Krt19, # Mm00492980_m1), tumor necrosis factor-alpha (TNF-α, # 
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Mm99999068_m1),  glyceraldehyde-3-phosphate dehydrogenase (GAPDH, # 
Mm99999915g1). Each 20 µL PCR reaction was performed in duplicate and consisted of 
1.766 ng RNA, 125 nM probe, 450 nM forward and 450 nM reverse primers and used 
qScript One-Step Fast MGB qRT-PCR master mix (low ROX) kit (# 95084, Quanta 
Biosciences, Gaithersburg, MD) according to manufacturer’s instructions. Real time RT-
qPCR was performed using a Stratagene Mx3005P™ QPCR system (Agilent Technologies, 
Inc, Santa Clara, CA) and the following cycling conditions: cDNA synthesis for 5 min at 
50ºC, denaturation for 30 s at 95°C, amplification for 50 cycles at 95°C for 3 s and at 60°C 
for 30 s. To determine the optimal RNA concentration for RT-qPCR reactions, a preliminary 
dilution study was performed from 1:21 to 1:50,000 on a mixture of all mouse RNA samples 
to determine the best range for each target standard curve. Calculations for the optimal 
dilution of each RNA sample and each final target standard curve was accomplished using 
PREXCEL-Q software (148). To normalize expression to epithelial cells (Larouche-2010), 
amplification of target mRNA was expressed relative to amplification of the keratin-19 
(Krt19) gene using the 2
-ΔCt
 method.  
Quantitative bacterial PCR 
The choice of probe and primers specific to the LGG is based on Ahlroos and Tynkkynen 
(149), who isolated and sequenced a unique random amplified polymorphic DNA band from 
LGG. This band is identified from a NCBI BLAST search as LGG insertion sequence ISLrh1 
transposase gene (GenBank: EU709012.1). To distinguish this gene as from the GG and not 
the 705 Lea rhamnosus strain and to choose an MGB probe, Primer Express 2.0 software 
(Applied Biosystems, Foster City, CA) was used over the area where there was a difference 
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in the SNP sequence between the two strains. The real time qPCR of LGG was as above, 
except that 0.0776 ng DNA was used in each sample PCR reaction with the following probes 
and primers specific to this strain and synthesized commercially (Applied Biosystems, Foster 
City, CA): probe (6FAM-ATCGCGCTTGAACG-MGB), forward primer (5’-
AAGTTCGCTTTTATGGGTAATGGA-3’) and reverse primer (5’-
GAAGGACTGCACGGTGTCACT-3’). Amplification of the target gene was expressed as 
relative DNA expression using the 2
-ΔCt
 method. 
Statistical analysis 
All data are expressed as means ± SE. Data was analyzed by individual F-tests for linear 
contrasts of means to assess the effects of diet, treatment, bacteria and the interactions of 
these factors on gene expression using the SAS GLM procedure and significant individual 
posthoc comparisons (P < 0.05) are indicated by groups with different letters.  
Results  
Mice were trained to meal feed in order to ensure complete intake of viable probiotic 
bacteria. The mice tolerated the experimental diets well and there was no significant 
difference in food intake among experimental groups (data not shown).  Without LGG, mice 
fed the casein diet and treated with DSS had lower final body weight compared to those not 
treated with DSS (Figure 1). However, this effect was ameliorated with the addition of the 
probiotic to the diet. Comparing the final body weights of mice treated with DSS to the 
casein group not treated with DSS, casein and whey protein diets resulted in lower body 
weights while soy protein diets did not. Addition of the probiotic to these diets also prevented 
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the decrease in final body weight.  
Colon length was reduced in mice fed the casein diet and treated with DSS compared to those 
not treated with DSS (Figure 2). Addition of the probiotic to the casein diet did not prevent 
the shortening of the colon in these animals. Within mice treated with DSS, colon length was 
greater in mice fed the soy protein diet compared to either casein or whey. The colon length 
of the mice fed the soy protein diet was not different from the casein fed mice without DSS 
treatment. Addition of probiotic had no effect on colon length for any treatment group. 
Quantification of LGG in fecal samples 
LGG was detected in the cecal contents of all mice fed LGG but none of those not given the 
probiotic (Table 2). Mice fed the whey protein diet had significantly higher LGG quantity 
compared to mice fed the casein or soy protein diets, but there was no significant difference 
between mice fed soy and those fed casein.  DSS treatment had no effect on expression of 
LGG in the mice.  
Colonic histological study 
 In colons of mice fed casein, DSS treatment produced an increase in most of the 
inflammatory parameters and addition of probiotic to the diet did not affect this response 
(Table 3). Among mice treated with DSS, casein and whey diets tended to produce similar 
changes in the colon with no differences due to probiotic feeding. One exception to this 
observation was that mice fed whey protein had significantly lower mucus layer thickness 
compared to the casein fed animals when both were fed the probiotic. In contrast, mice fed 
soy protein and treated with DSS tended to have colon inflammatory measures similar to the 
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casein fed mice without DSS, and this was similar with or without probiotic (Figure 3). Also, 
mice fed the soy protein diet without probiotic had significantly higher goblet cells per crypt 
compared to the other treatment groups (without probiotic). This effect of soy protein was 
not present when comparing within animals fed the probiotic.    
MUC gene expression in colon and cecum 
In mice fed casein, MUC1 gene expression was increased by DSS treatment (Figure 4A). 
Among the mice treated with DSS, casein and whey protein diets resulted in similar levels of 
MUC1-specific mRNA expression while those fed soy protein had significantly (p < 0.05) 
lower levels. Addition of probiotic to the diets did not influence MUC1 gene expression. In 
the cecum, DSS also induced MUC1 gene expression in mice fed casein (Figure 4B). After 
DSS treatment, MUC1 gene expression was similar in mice fed the three dietary proteins, 
although the soy fed animals had levels that were not statistically different from the casein 
fed animals without DSS. Among the MUC2, MUC3 and MUC4 genes, expression was not 
significantly altered by DSS treatment in mice fed casein in either colon or cecum (Table 4). 
Overall, diet and probiotic treatment had little effect on MUC2, 3 or 4 gene expression in the 
colon or cecum. However, MUC2 and MUC4 expression were significantly higher in colon 
of mice fed soy protein compared to casein when neither group received the probiotic. And in 
the cecum, MUC3 expression was higher in mice fed soy protein compared to whey when no 
probiotic was fed. When the mice were given the probiotic, diet had no effect on MUC2, 3 or 
4 expression in the colon, but in the cecum, expression of MUC3 was less in mice fed casein 
compared to soy or whey.   
TFF gene expression in colon and cecum 
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In mice fed casein, adding the probiotic to the diet significantly increased expression of 
TFF3 in the colon (Figure 5A). DSS treatment also increased TFF3 in casein fed animals, 
and the increase was greater when the mice consumed the probiotic. However, after DSS 
treatment TFF3 expression in the colon was lower in mice fed soy or whey protein compared 
to casein, and there was no effect of the probiotic in these animals. The expression of TFF3 
in the animals fed soy or whey protein and treated with DSS was not different from that in 
mice fed casein without DSS treatment.  A different pattern in TFF3 expression was 
observed in the cecum with lower expression following DSS treatment in the casein fed 
animals and a further decrease in mice fed the probiotic with DSS (Figure 5B). In DSS 
treated mice fed the soy or whey protein diets, TFF3 expression in the cecum was not 
affected by the probiotic and levels were not different from the casein fed animals without 
DSS. TFF2 gene expression was not affected by DSS, diet or probiotic in the colon, 
however, in the cecum it was increased by probiotic feeding in all diet groups (data not 
shown).  
TNF-α gene expression in colon and cecum  
TNF-α gene expression was significantly higher in casein fed animals following DSS 
treatment in both the colon (Figure 6A) and the cecum (Figure 6B). In mice treated with 
DSS and fed soy protein however, TNF-α expression was lower than in mice fed casein or 
whey. Addition of the probiotic to the diet only affected expression of TNF-α in the cecum of 
mice fed whey protein.   
Comparisons of MUC, TFF genes in control and DSS groups in colon and cecum  
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The relative gene expression of the inflammatory markers in colonic (Figure 7A) and cecal 
tissue (Figure 7B) in response to DSS were compared. In colon of mice not treated with 
DSS, MUC3 was the most abundant, followed by MUC2, MUC4, and MUC1. TFF2 was 
poorly expressed, whereas TFF3 was abundant. CK19 and GAPDH were similarly expressed 
in colon and cecum. With DSS treatment, colonic expression of MUC1, TFF3, and TNF-α 
were significantly increased (p < 0.05), while MUC3 was suppressed. In the cecum, only 
MUC1 and TNF-α were increased with DSS while TFF3 and CK19 were suppressed.    
Discussion  
Given the current increase in IBD in the United States, finding dietary interventions to reduce 
or alleviate symptoms is urgently needed. It is becoming increasingly evident that dietary 
factors and colonic microbiota play significant roles in modulating symptoms of IBD and 
that there are complex interactions between dietary components and microbial populations. 
Hence, it is of value to carry out research that combines studies of microbial and dietary 
interventions in models of IBD. To clarify these interactions, we quantified the probiotic 
population in the lower bowel following oral supplementation in animals fed different 
sources of protein. Whey protein resulted in a four-fold higher expression of LGG in the 
cecum compared to casein, which was consistent with previous findings by Sprong et al. 
(125). They found that cheese whey protein administration increased the amount of 
Lactobacillus and Bifidobacteria in fecal samples of rats compared to casein. This effect may 
be attributed to certain components in the whey protein, such as glycomacropeptide or 
lactoferrin, which are not present in casein. A previous study found that they supported the 
growth of Bifidobacteria and Lactobacillus and suggested support of gut health (124). In 
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addition, threonine and cysteine that are abundant in whey protein were proved to promote 
the growth of Bifidobacteria and Lactobacillus in rats (125). Soy protein did not support 
retention of LGG in the present study. Recent reports about the prebiotic potential of soy 
protein are controversial. Tsinberg et al. (143) found that hydrolysate-soybean media 
promoted a higher growth rate of the Bifidobacteria and Lactobacillus, whereas Pham et al. 
(144) observed that the addition of soy protein did not increase the growth of probiotic 
microorganisms. It is clear that soy protein are not uniform in their ability to support the 
growth of probiotics, hence a careful, systematic assessment of soy protein and probiotic 
interactions is needed and illustrates the importance of quantifying probiotic survival. 
The DSS induced colitis model applied in the present study is a well-established and 
generally accepted model for human colitis. In general, DSS treatment causes weight loss, 
diarrhea, shortening of the colon, erosion of the mucosal epithelium, and acute neutrophilic 
infiltration (81, 87). TNF-α is also a well-documented inflammatory marker that is increased 
in DSS-induced colitis models (87, 89, 90). In our study, the animals were euthanized within 
24 hours after ending DSS treatment, hence we examined very early changes in intestinal 
response. Even at this early phase, colon length was significantly reduced by DSS in mice 
fed casein or whey. Additionally, the proinflammatory cytokine TNF-α was induced in both 
colon and cecum in mice fed casein or whey, which further confirmed colitis in these DSS 
treated mice. The soy fed mice, in contrast, did not experience these changes, suggesting an 
anti-inflammatory effect of soy protein, which is in concordance with previous studies (139, 
140). The isoflavones in soybean were found to exert anti-inflammatory effects, including 
reducing colonic expression of COX-2 mRNA and protein and decreasing MPO activity in 
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TNBS induced colitis animal model (136).  However, the soy protein we used was depleted 
of isoflavones, therefore we may exclude the contribution of isoflavones to these anti-
inflammatory effects. De Mejia et al. (139) found that a bioactive peptide named lunasin, 
purified from defatted soybean flour, inhibited the pro-inflammatory markers such as IL-1β, 
IL-6, NF-κB transactivation, COX-2 expression, and nitric oxide synthase expression in 
RAW 264.7 macrophages.  Similarly, Hernández-Ledesma et al. (140) used LPS-stimulated 
RAW 264.7 macrophages to study the anti-inflammatory effects of lunasin. They observed 
that lunasin reduced the production of reactive oxygen species (ROS) by LPS-induced 
macrophages in a significant dose-dependent manner and inhibited the release of pro-
inflammatory cytokines TNF-α and IL-6.  
Our working hypothesis was that diet and/or probiotic bacterium feeding could generate a 
protective effect in the IBD model through regulation of the mucin and trefoil factor genes. 
These factors have been implicated previously to be critical in the progression and severity of 
IBD. Mucins are a family of high molecular weight, heavily glycosylated proteins produced 
by goblet cells. The mucous layer lining the surface epithelium of the intestine acts as a 
lubricant and protective physical barrier between the mucosal surface and the luminal 
contents (2). MUC1, MUC2, MUC3 and MUC4 are the major mucins expressed in the large 
intestine in humans (23). The mucin genes in mice are similar to human. It has been found in 
the BALB/C mice that MUC3 is the most commonly expressed mucin in the large intestine, 
followed by MUC2. In contrast, MUC1 and MUC4 are poorly expressed (24). The trefoil 
factor (TFF) peptides are a family of small protease-resistant proteins characterized by one or 
more trefoil motifs (150). TFF1, TFF2, and TFF3 are expressed in mucus-secreting cells, 
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mainly in the GI tract, with specific cellular localization of each peptide. TFF1 is expressed 
in surface epithelial cells of the stomach, and TFF2 in mucous neck cells, pyloric glands, and 
Brunner’s glands, whereas TFF3 is mainly located in goblet cells of the small and large 
intestine (26). As is well known, the mucous layer that consists of mucins and trefoil factors 
secreted by goblet cells forms the first barrier against pathogens in the gut (19, 20). MUC and 
TFF genes are critical for protecting the intestine from inflammation. In addition, MUC1 
plays a role in regulating the cell growth and the differentiation via the mitogen-activated 
protein kinase pathway (151). In vitro experiments demonstrated that TFF3 enhanced the 
expression of decay-accelerating factor (DAF), which is another important mucosal 
defensive protein interrupting the complement activation pathways, and thus protected the 
tissues from autologous complement injury (99, 100). The upregulation of these genes in the 
early stage of acute colitis indicates the role of MUC1 and TFF3 in the response to injury and 
maintaining the mucosal barrier integrity (24).  
 Among the MUC genes, MUC1 is most associated with IBD. Overexpression of MUC1 was 
found in the serum and colon biopsies of IBD patients and increased MUC1 levels correlated 
with clinical disease severity (92). Additionally, in BALB/C mice, MUC1 gene expression 
was enhanced significantly by DSS treatment (24). In these animals, alteration of MUC1 
suggested that mucin production was adapted to maintain and recover the protective 
capacities of the mucus layer, which were changed during experimental colitis (24). In 
agreement with these findings, we found DSS increased MUC1 gene expression in both the 
colon and the cecum. This suggested that in the inflammatory condition caused by DSS 
treatment, a compensation of MUC1 gene expression was stimulated in order to maintain the 
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protective capacities of the mucus layer and prevent the colon from further damage.  
In the casein fed mice, MUC2, MUC3 and MUC4 gene expression was not altered by DSS 
treatment in either colon or cecum in the present study. This is in contrast to previous 
findings. MUC2 in the colon was increased following 5% DSS treatment for 9 days  in 
Sprague Dawley rats (93). In Wistar rats treated with 7% DSS for 7 days, colonic MUC2 
started to increase 2 days after the DSS treatment, and the increase was maintained during the 
regenerative phase only in the proximal colon (94). However, in BALB/C mice MUC2 was 
not changed following a 5 day treatment with 1% DSS when the mice were euthanized right 
after the DSS treatment (24). MUC3 and MUC4 were increased the day after a 5-day 1% 
DSS treatment in BALB/C mice and 9-day 5% DSS treatment in Sprague Dawley rats (24, 
93). These discrepancies in MUC2, MUC3 and MUC4 response to DSS may be a result of 
differences in the animal models and or severity of the inflammatory response. MUC2 
seemed to be induced immediately after a longer period of high dose (5% and 9%) DSS in 
rats, but not after 5-day treatment with a low dose (1%) in BALB/C mice, which might 
suggest that MUC2 induction occurs in more severe inflammation. Both MUC3 and MUC4 
were induced immediately after 5-day 1% DSS treatment in BALB/C mice and 9-day 5% 
DSS treatment in Sprague Dawley rats, which suggested that MUC3 and MUC4 might be 
induced early after moderate inflammation in some animal stains.  
We observed in casein fed mice that TFF3 expression was induced by DSS in the colon, as 
was previously reported. Renes et al. (94) treated Wistar rats with 7% DSS in the drinking 
water for 7 days, followed by a 3 week recovery period. By Immunohistochemistry, TFF3 
was expressed in the upper crypts in the proximal colon and upper two-thirds of the crypts in 
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the distal colon. On day 2 of DSS treatment, TFF3 positive goblet cells accumulated in the 
surface epithelium in the entire colon. As DSS administration progressed (day 5 and 7), there 
were more TFF3 positive goblets cells found in the surface epithelium. Protein dot blotting 
showed an increase of TFF3 peptide in the colon samples (94). Consistently, it was observed 
in the DSS-induced colitis BALB/C mice model that both TFF3 peptide and mRNA were 
increased (24, 98). TFF2 was not induced in either the colon or cecum by DSS in the present 
study, which is in agreement with previous findings (98). This contrasts with findings in IBD 
patients where TFF2 mRNA was not changed significantly in DSS-induced colitis of mice, 
which indicates that DSS-induced colitis might have an acute pathology, while IBD lesions 
exhibit a more chronic nature (98). A significant finding of our study was that, soy protein 
significantly suppressed the increase in MUC1, TFF3 and TNF-α caused by DSS in the 
colon, while neither casein nor whey had this effect. A primary component of soy that has 
been well studied for bioactivity is the estrogenic isoflavone. However, the soy protein we 
used was processed to remove the majority of the isoflavones, hence these compounds cannot 
explain the current findings. However, other potentially bioactive compounds in soy have 
also been identified. De Mejia et al. (139) and Hernández-Ledesma et al. (140) found that the 
soy-specific compound lunasin had anti-inflammation effects via inhibiting the NF-κB 
pathway in macrophages. In their studies, NF-κB transactivation, IL-1β, IL-6, TNF-α, COX-
2 expression and nitric oxide synthase expression were suppressed by lunasin (139, 140). We 
did not quantify lunasin in our soy protein; however, information on lunasin concentration of 
soybean cultivars and commercial soy proteins is available in another publication. De Mejia 
et al. (152) used a developed ELISA method to identify lunasin and quantify the variations in 
concentration in 144 selected, diverse soybean accessions. They found that soy protein 
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concentrate, isolate, and hydrolyzate contained 2.8, 3.75, and 4.4 g lunasin/100 g flour, 
respectively, while soy flour and soy flakes contained 1.24 g lunasin/100 g flour. There was 
very little or no lunasin in isoflavone-enriched products (152). In our study, the mice ate 
about 4g of the diet each day, which contained 1.1g soy protein concentrate. The lunasin in 
soy protein concentrate was approximately 2.8 g/100g, thus the daily intake of lunasin for the 
mice was about 30.8 mg/day. There is no available data about the dose of lunasin in an 
animal study yet, thus we could not compare the dose in our study with other publications 
and confidently decide if the amount of lunasin consumed by the mice would be significant. 
Given the finding that soy protein affected the mucosal barrier markers in our study, further 
study of the potential mechanisms, and/or bioactive components seems warranted. 
Neither casein nor whey protein alleviated colitis symptoms, histological parameters, or 
expression of TNF-α, indicating that dairy proteins did not have protective effects against 
DSS-induced colitis. Whey protein did not change the MUC gene expression in the present 
study, which was in accordance with the observation by Sprong et al. (125). They found that 
feeding 16% cheese whey protein increased the mucin production in the feces of DSS-treated 
rats without altering MUC gene expression (125). They also found that animals fed casein 
supplemented with threonine and cysteine exhibited a similar response, suggesting that these 
amino acids, which are the major amino acid constituents of GI secretory mucins (126), may 
provide the protective effect.  
Gupta et al. (113) observed that administration of 10
10 
colony-forming units of LGG twice 
daily for 6 months was beneficial to children with mildly to moderately active Crohn’s 
disease. LGG feeding decreased disease activity within one week and the protective effect 
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was maintained throughout the study period. Similarly in rats, LGG administration decreased 
myeloperoxidase activity following TNBS treatment (115). In contrast to these previous 
studies, we found no effect of the probiotic on the inflammatory parameters in the colon or 
cecum. In fact, the soy diet which retained the lowest level of LGG in the cecal contents was 
the most effective in ameliorating the effects of DSS, while the whey protein diet that 
generated the highest cecal load of LGG was largely ineffective. Hence, our hypothesis that a 
diet which supports optimal probiotic survival would generate the largest protective effect 
was not supported for LGG specifically in the current study. 
In summary, we demonstrated that MUC1 and TFF3 gene expression were increased by DSS 
treatment. In mice fed soy protein, induction of MUC1 and TFF3 was suppressed. Whey and 
casein protein diets and LGG at the levels selected for this study were ineffective in altering 
the inflammatory or mucosal barrier parameters. As a marker of inflammation, TNF-α gene 
expression was increased after DSS treatment. Mice fed soy protein, however, had 
suppressed TNF-α expression compared to the other treatment groups, which was consistent 
with the colon length and histological measures. In conclusion, soy protein suppressed the 
DSS-induced inflammatory stimulation of MUC, TFF and TNF-α gene expression 
independently of the probiotic. Whey protein may act as prebiotic in the colon to increase 
microbial survival, but these factors failed to prevent the inflammatory response in the DSS 
induced colitis mouse model. 
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Figure 1 Final body weight of mice fed casein, soy or whey protein diets with or without 
LGG.  Values are mean ± SE, n = 6-10. Means without a common letter differ, P < 0.05. 
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Figure 2 Length of colon from mice fed casein, soy or whey protein diets with or without 
LGG.  Values are mean ± SE, n = 6-10. Means without a common letter differ, P < 0.05.  
 
 
 
 
0
1
2
3
4
5
6
7
casein, control casein, DSS soy, DSS whey, DSS
no LGG
LGG
C
o
lo
n
 l
e
n
g
th
(c
m
)
b
b
b
b
aa
n =     6        6 10       7 9       6 9        8
a
a
51 
 
 
 
 
Figure 3 Colon inflammation score from mice fed casein, soy or whey protein diets with or 
without LGG.  Values are mean ± SE, n = 6-10. Means without a common letter differ, P < 
0.05.  
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Figure 4 mRNA expression of MUC1 gene in mouse colon (A) and cecum (B) in mice fed 
casein, soy or whey protein diets with or without LGG. MUC1 gene expression was 
quantified by quantitative real-time PCR and data were normalized to keratin 19 expression.  
Values are mean ± SE, n = 6-10. Means without a common letter differ, P < 0.05.  
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Figure 5 mRNA expression of TFF3 gene in mouse colon (A) and cecum (B) in mice fed 
casein, soy or whey protein diets with or without LGG. TFF3 gene expression was quantified 
by quantitative real-time PCR and data were normalized to keratin 19 expression.  Values are 
mean ± SE, n = 6-10. Means without a common letter differ, P < 0.05.  
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Figure 6 mRNA expression of TNF-α gene in mouse colon (A) and cecum (B) in mice fed 
casein, soy or whey protein diets with or without LGG. TNF-α gene expression was 
quantified by quantitative real-time PCR and data were normalized to keratin 19 expression.  
Values are mean ± SE, n = 6-10. Means without a common letter differ, P < 0.05.  
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Figure 7 Comparisons of colonic (A) and cecal (B) MUC, TFF, keratin 19 and GAPDH gene 
expression in control or DSS treated mice. All diet and probiotic treatments combined. Gene 
expression was quantified by quantitative real-time PCR. The data was not normalized to 
internal control gene.  Values are mean ± SE, n = 6-10. A significant DSS effect (P < 0.05) 
between casein groups indicated with black brackets.  
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Table 2  Effect of diets on relative expression of LGG transposase gene in mouse cecal contents
1
 
                    
  Diets without LGG  Diets with LGG 
 Casein Soy Whey  Casein Soy Whey 
 control DSS DSS DSS  control DSS DSS DSS 
 n = 6 n = 10 n = 9 n = 9  n = 6 n = 7 n = 6 n = 8 
LGG transposase
2
 ND
3
 ND ND ND   16.35 ± 7.62
b
 12.78 ± 5.18
bc
 3.90 ± 1.66
bc
 52.07 ± 13.1
a
 
   
   
1
 values are means ± SE. Means without a common letter differ, P < 0.05. 
2
 probe and primers were used that are specific to LGG. 
3
 ND: not detectable. 
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Table 3  Effects of 2% DSS and diet on mouse colon histology
1
    
                  
Colon histological 
measurements 
Diets without LGG  Diets with LGG 
Casein Soy Whey Casein Soy Whey 
control DSS DSS DSS control DSS DSS DSS 
n = 4-5 n = 9 n = 9 n = 7 N = 6 n = 4 n = 6 n = 6 
inflammation score
2
 0.40 ± 0.2
cd
 0.90 ± 0.2
bc
 0.30 ± 0.2
d
(9) 1.40 ± 0.3
ab
(8) 0.30 ± 0.2
cd
 1.50 ± 0.3
ab
 0.00 ± 0.0
d
 1.80 ± 0.2
a
 
crypt layer thickness
3
 1.48 ± 0.08
d
 2.00 ± 0.18
bc
 1.80 ± 0.07
cd
 2.08 ± 0.14
bc
 1.91 ± 0.11
bd
 2.35 ± 0.35
ab
 1.89 ± 0.12
bd
 2.69 ± 0.18
a
 
Inflammatory layer thickness 0.47 ± 0.08
d
 0.92 ± 0.09
c
 0.50 ± 0.06
d
 1.09 ± 0.12
c
 0.50 ± 0.15
d
 1.12 ± 0.25
bc
 0.31 ± 0.03
d
 1.40 ± 0.10
ab
 
muscle layer thickness 1.14 ± 0.14
b
 1.56 ± 0.16
ab
 1.84 ± 0.18
a
 1.57 ± 0.13
ab
 1.73 ± 0.20
ab
 2.04 ± 0.32
a
 1.91 ± 0.43
a
 2.06 ± 0.14
a
 
total thickness 3.09 ± 0.27
d
 4.49 ± 0.36
bc
 4.14 ± 0.14
cd
 4.74 ± 0.29
bc
 4.13 ± 0.42
cd
 5.51 ± 0.86
ab
 4.11 ± 0.48
cd
 6.15 ± 0.29
a
 
mucus layer thickness 0.58 ± 0.14
b
 0.48 ± 0.04
b
 0.47 ± 0.07
b
 0.49 ± 0.05
b
 0.57 ± 0.14
b
 1.31 ± 0.44
a
 0.60 ± 0.08
b
 0.53 ± 0.07
b
 
goblet cells per crypt 7.10 ± 1.0
b
 8.90 ± 0.9
b
 13.90 ± 1.2
a
 7.90 ± 0.5
b
 9.10 ± 0.7
b
 8.00 ± 0.6
b
 9.20 ± 0.8
b
 7.20 ± 0.6
b
 
  
1
 values are means ± SE for the number of mice indicated (exceptions in parenthesis) averaged for 2-4 regions per cross section of alcian blue-
stained colon slide.  Means in a row with superscripts without a common letter differ, P <0.05.  
2
 inflammation scoring is as in Materials and Methods. 
3
 Thicknesses are measured in microns (µm). 
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Table 4  Effects of 2% DSS and diet on relative mRNA expression in mouse colon and cecum
1
   
                  
mRNA 
Diets without LGG   Diets with LGG 
Casein 
Soy Whey 
 Casein 
Soy Whey 
Control DSS DSS DSS 
 
control DSS DSS DSS 
n = 6 n = 10 n = 9 n = 9   n = 6 n = 6 n = 6 n = 7 
          
colon          
Mucin-2 0.813 ± 0.301ab 0.826 ± 0.072b 1.335 ± 0.159a 0.891 ± 0.125ab 
 
1.014 ± 0.084ab 1.354 ± 0.423a(7) 1.094 ± 0.150ab 0.972 ± 0.073ab(8) 
Mucin-3 1.175 ± 0.079b 0.900 ± 0.085bc 0.910 ± 0.088bc 0.776 ± 0.066c 
 
1.627 ± 0.325a 0.908 ± 0.116bc 0.931 ± 0.165bc 0.789 ± 0.074c(8) 
Mucin-4 0.718 ± 0.186b 0.807 ± 0.109b 1.323 ± 0.213a 1.077 ± 0.205ab 
 
0.751 ± 0.108b 0.844 ± 0.280ab 1.015 ± 0.109ab 0.890 ± 0.129ab(8) 
          
cecum 
         
Mucin-2 0.846 ± 0.088ab 0.918 ± 0.047b 0.694 ± 0.067b 1.054 ± 0.059a 
 
1.014 ± 0.133a 0.894 ± 0.081ab(7) 1.010 ± 0.130a 1.039 ± 0.038a 
Mucin-3 0.874 ± 0.068c 1.075 ± 0.072bc 1.305 ± 0.083ab 1.019 ± 0.066c 
 
1.009 ± 0.063c 0.837 ± 0.055c 1.510 ± 0.135a 1.407 ± 0.201a 
Mucin-4 0.478 ± 0.075d 0.535 ± 0.064d 0.719 ± 0.110ac 0.535 ± 0.100bc   0.598 ± 0.108bc 0.521 ± 0.062bc 0.850 ± 0.152ab 0.808 ± 0.173bc 
 
1
 values are means ± SE for the n values indicated (exceptions in parenthesis). Means without a common letter differ, P < 0.05.  
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CHAPTER 3 
DISCUSSION 
Probiotic bacteria have been utilized for health benefits for several decades (106). Probiotics 
have been found to promote a healthy state of the GI tract and have been applied to prevent 
and treat several intestinal inflammatory disorders, such as necrotizing enterocolitis and 
inflammatory bowel disease (IBD) (31, 109-112). Evidence suggests that probiotics have 
certain effects on the modulation of intestinal barrier function in both normal and 
inflammatory conditions (112, 116-118). 
Recently, soy and whey proteins have gained popularity as nutrition supplements in the 
market. They both have various potential modes of action for protecting human health. Soy 
protein has been shown to have protective effects on colon cancer, although the mechanisms 
are not well defined (129, 130). Animal studies have found that soy protein improved the 
intestinal barrier function and reduced bacteria translocation in the gut (132). In addition, it 
has been found that soy protein had anti-inflammation effects via inhibiting the NF-κB 
pathway in macrophages (139, 140). Whey protein contains bioactive components such as 
glycomacropeptide and lactoferrin, which may be beneficial in preventing colitis (122, 123). 
Glycomacropeptide and lactoferrin also have prebiotic properties that have been shown to 
support the growth of Bifidobacteria and Lactobacillus and thereby promoting gut health 
(124, 125). In addition, threonine and cysteine that are abundant in whey protein were proved 
to promote the growth of Bifidobacteria and Lactobacillus in rats (125).  
Therefore, we designed the present study to investigate whether a probiotic bacterium, in 
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combination with casein, soy or whey protein would have protective effects on colitis, with 
special focus on modulation of the mucous barrier. Since casein is used as the basic protein 
source in the AIN 93 rodent diet formulation (121), we used it as the control diet in our study. 
Both casein and whey protein are derived from cow milk and they are easily digestible 
proteins. The digestibility rates of casein and whey protein in rats were 99% and 100%, 
respectively (153). Soy protein is somewhat less digestible. The apparent ileal digestibility of 
soy protein concentrate was 75.4% in growing pigs (154). The casein used in our study was 
95% purity, whereas the soy protein and whey protein included some other components 
(Table 7). The soy protein contained 69% protein, 19% fiber and 3% fat and 7% ash. The 
whey protein contained 81.5% protein, 5.5% fat, 6% lactose and 3% ash. Not only casein, but 
also whey protein and soy protein were good sources of essential amino acids (EAAs). They 
provided sufficient EAAs for the growing mice (Table 8). We proposed that the specific 
bioactive components or amino acids in the soy protein and whey protein could affect the gut 
microbiota and barrier function, thereby modulating colitis.  
We chose the DSS animal model based on our previous experiments. Our lab had previously 
tested different doses of DSS (1%, 2% and 3%) in C57BL/6 female mice. It was found that 
treating the C56BL/6 mice with 2% DSS for 4 days resulted in moderate colitis, defined by 
the MPO activity and the changes of several proinflammatory cytokines such as IL-1β, IL-6, 
and TNF-α. The dose and administration period for LGG were based on previous 
publications by others (116, 153). The diet was prepared according to AIN 93 rodent diet 
formulation, with relative changes in the protein sources. Because we wanted to investigate 
the protective effects of the probiotic/diet in this study, we euthanized the animal just one day 
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after finishing the DSS treatment without giving the mice a recovery period. To investigate 
how these conditions would influence colitis recovery, another study using a different end 
point would need to be done. 
The chronic inflammation can be induced by 5-9 day high dose DSS treatment followed by 
2-4 week low dose DSS treatment. Hoebler et al. (24) treated BALB/c mice with 1% DSS for 
5 days to induce acute inflammation, followed by 0.5% DSS for 28 days to induce chronic 
inflammation. It was found that MUC3 mRNA level was increased after acute colitis. MUC1 
and MUC4 gene expression were enhanced significantly by colitis (24). In another study, 
Sprague-Dawley rats were administered 5% DSS for 9 days followed by 2% DSS for 18 days 
to induce chronic colitis (93). It was observed that DSS-treated rats had higher mRNA levels 
of colonic MUC2 and MUC3 compared with pair-fed controls (93). In the study by Renes et 
al. (94), Wistar rats were given 7% DSS in the drinking water for 7 days, followed by a 3 
week recovery period. Biochemical analysis of MUC2 protein levels showed a progressive 
increase in MUC2 in the proximal colon during DSS treatment, and MUC2 levels rose to 
fourfold of the control levels on day 7. If we extend the DSS treatment in our study, for 
instance, continue 1% DSS treatment for 3 weeks after the 4-day 2% DSS treatment, we may 
develop a chronic inflammation model. According to the chronic inflammation models 
mentioned above, we may see the induction of MUC2, MUC3 and MUC4 by DSS. We 
expect that soy protein would suppress these MUC genes. Because the administration time of 
the LGG and whey protein is extended, we might expect that the probiotic and whey protein 
show a protective effect against colitis.  
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A limitation about the experimental design of the present study was that we did not include 
groups of mice fed soy or whey protein without DSS treatment. This was partially attributed 
to budget limitations. If we included these groups, there would be four more groups, thus 12 
groups in total. Another consideration was that, the DSS effects on the parameters could be 
observed within the casein groups which did have with or without DSS.  But our primary aim 
was to compare the differences of the MUC, TFF gene expression and inflammatory markers 
in colitis animals among different diet groups, which was achieved with the present 
experimental design.  
In our study, we only tested one specific strain of probiotic, the LGG, which has been found 
beneficial in Crohn’s diseases (113). LGG did not show a protective effect at the level 
selected for this study. Besides LGG, other strains of Lactobacillus or Bifidobacteria may be 
used. For example, the commercial probiotics mixture VSL#3 containing 3 Bifidobacterium 
stains (breve, longum, and infantis), 4 Lactobacillus stains (acidophilus, plantarum, 
paracasei, and bulgaricus) and Streptococcus thermophilus has been utilized widely in 
publications exploring how probiotics affect IBD (116, 153, 154). In healthy Wistar rats, it 
was observed that oral administration of VSL#3 on a daily basis for 7 days increased basal 
luminal mucin content by 60%. The isolated rat colonic loops that exposed to the probiotic 
formula increased the amount of mucin secretion and a higher gene expression of MUC2. 
Meanwhile, MUC1 and MUC3 gene expression were slightly increased (116). Another 
animal study by Fitzpatrick et al. (155) found that the probiotic formulation VSL#3 improved 
DSS-induced colitis in weaning rats. Colonic IL-1β, MPO activity were decreased by the 
probiotic application. Sood et al. (156) found the patients with mild-to-moderately active 
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ulcerative colitis had significantly greater decreases in disease scores and individual 
symptoms after 6-week VSL#3 administration, compared with the placebo group. 
There are other diet factors that may influence the mucus barrier. Butyrate, an end-product of 
carbohydrate fermentation, was found to modulate the secretion of mucins (157, 158). 
Gaudier et al. (158) treated mice daily for 7 days by rectal enemas of butyrate (100 mM) 
versus saline. They demonstrated that butyrate stimulated the gene expression of both 
secreted (MUC2) and membrane-linked (MUC1, MUC3, MUC4) mucins in the colon without 
changing the number of MUC2-positive epithelial cells. However, butyrate caused a 2-fold 
decrease in the thickness of adherent mucus layer, which needed further studies to explore 
the mechanisms. Since dietary fibers could be fermented by the microbes in the colon and 
produce butyrate (159), we may also test different fibers and determine how they would 
modulate the mucus barrier.  
 
Discussion about the methods in the present study 
1. New method for probiotic administration 
In the present study, we developed a new method to administer LGG. Instead of using 
orogastric gavage to introduce the probiotic into the stomach of the mice as previously 
reported (116, 160), we added the LGG, resuspended in PBS, on the top of wet diets and then 
meal-fed the mice. The mice had been adjusted to the meal-fed method before we started the 
experimental period and they consumed most of the food during the allowed feeding time, 
thus we could ensure the LGG intake. There was no diet effect, probiotic effect on the food 
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consumption. During the DSS treatment period, the food consumption in the DSS groups was 
decreased compared the control groups, but the food consumption decrease seemed less 
obvious in the soy protein groups (Table 5A and 5B). The mice body weight decreased 
during the acclimation time, but increased when we started the experimental period (Figure 
8). Over the 4-day DSS treatment, most of mice did not lose weight, but the average body 
weight gain was reduced in the DSS groups compared to the groups without DSS treatment. 
There was no significant difference between the diet groups, and LGG did not show 
significant effect on the body weight change (Figure 9).  There was no significant difference 
in body weight gain among the casein, soy protein and whey protein groups. In addition, we 
conducted an experiment to test the viability of LGG after being left in the diet for 2 hours 
and the result confirmed that LGG remained viable. After 1h in the soy diet (mixed with 110% 
water), the concentration of LGG changed from 3x10
10
CFU/ml to 1x10
10
CFU/ml. The 
concentration after 2h was 1.5x10
10
CFU/ml. In the casein diet (mixed with 40% water), the 
concentrations of LGG after 1h and 2h were 2x10
8
CFU/ml and 1x10
8
CFU/ml, respectively. 
Given that the amount of LGG rarely declined within the test time, we presumed that the 
LGG would stay viable in the diet within the feeding time (5h). Therefore, our method to 
administer LGG was feasible. An obvious advantage of this method was that it did not 
produce stress in the animals as would have occurred with gavage administration. De Meijer 
et al. (161) observed that orogastric gavage increased stress and affected food intake when 
trying to develop a diet-induced obesity murine model. They suggested that the laboratory 
routines, such as orogastric gavage, may intervene in the results of the experiments and 
should be taken into account when designing animal studies.  
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2. Goblet cell staining 
In the current study, the histological sections were stained with 1% alcian blue for goblet cell 
quantification (146). The alcian blue stain is a popular staining method in histology. At a pH 
of 2.5, the alcian blue will stain for both sulfated (sulphomucins) and carboxylated 
(sialomucins) mucopolysaccharides which are found in the goblet cells located in the 
intestine. The alcian blue dye is a positively charged, very large molecule that will bind to the 
negatively charged low density mucin found in the goblet cells, staining it blue in color (162). 
In general, the goblets cells were stained well in our study, however, the boundary of some 
goblet cells were not clear, and there was some non-specific staining, which made it difficult 
to count the numbers of the cells in each crypt. An alternative to measuring goblet cell 
density would be immunohistochemical staining using an anti-mucosal epithelial membrane 
mucin antibody (163). The specific antibody-antigen binding can stain the goblet cells in a 
more specific manner and may improve the accuracy of the quantification.  
3. Mucin synthesis measurement 
Mucin synthesis rates would be a direct measure of the mucin expression.  Other researchers 
have quantified mucin synthesis (125, 127). Sprong et al. (125)  analyzed  fecal mucin in rats 
treated with DSS. Briefly, fecal mucin was extracted from freeze-dried feces and quantified 
fluorometrically as previously described by Bovee-Oudenhoven et al. (164). Mucin synthesis 
rates can also be measured in vivo. Faure et al. (93) determined  mucin synthesis rates in the 
rats using  gas chromatography-combustion-isotope ratio mass spectrometry with purified 
mucins from the intestine. 
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4. Histological study 
The parameters we used in the present study included the inflammation score, thickness of 
crypt layer (from the luminal end of the crypt to the surface of the thin basal muscle layer), 
the thickness of the inflammatory layer (from the surface of the thin basal muscle layer under 
the crypts to the surface of the lower thicker muscle layer) and thickness of the whole colon, 
which have been widely used by others (160, 165). The inflammation score was based on the 
morphological criteria described in by Suzuki et al. (147): 0 = normal colon mucosa; 1 = 
shortening the basal 1/3 of crypts with slight inflammation and edema in the lamina propria; 
2 = loss of the basal two-thirds of the crypts with moderate inflammation in the lamina 
propria; 3 = loss of all the crypts with severe inflammation in the lamina propria, but with the 
surface epithelium still remaining; 4 = a loss of all the crypts and surface epithelium with 
severe inflammation in the mucosa, muscularis propria and submucosa.  
An additional parameter that could be used in the future is the counting of 
polymorphonuclear neutrophil granulocytes (PMN) in the colon sections. PMN is the most 
abundant cell type in intestinal lesions in IBD (166). It was found that DSS-induced colitis in 
mice was characterized by PMN infiltration into the colonic mucosa. Thus, the quantification 
of PMN within the lamina propria could be used as an inflammatory marker in DSS-induced 
colitis (167).  
 
5. LGG quantification in fecal samples 
In our study, we used quantitative RT-PCR to quantify the amount of LGG in the fecal 
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samples. The 16S rDNA gene sequence is widely used as a target for genus- and species-
level identification. We extracted the fecal DNA and amplified the specific gene (L. 
rhamnosus transposase) and calculated the relative amount of LGG.  LGG-specific gene 
expression was found in cecum contents of all mice given LGG but none of the untreated 
mice. We housed the mice in separate rooms and made specific effort to prevent cross 
contamination, which was very successful. Mice fed whey protein had significantly higher 
LGG expression than the other diet groups; therefore we concluded that the quantitative RT-
PCR was a reliable method.  Another way to quantify probiotic recovery from the intestine 
would be the bacteria culture method. As described by Nanda Kumar et al. (160), feces 
samples are collected from cecum and diluted. The bacteria can be cultured in MRS medium 
in an anaerobic incubator for 24 hours, and the number of the LGG colonies counted. 
 
Future work 
1. Identify the bioactive components in the soy protein that modulate the barrier function. 
We found that soy protein mediated the abnormal expression of MUC and TFF genes in DSS 
treated animals, which indicated the potential of soy protein in preventing or treating IBD or 
other intestinal diseases. However, further studies are needed to identify the bioactive 
components in the soy protein. 
The protective effects of soy protein could attribute to the three aspects. Firstly, the soy 
protein concentrate we used in our study is not pure protein. It is a mixture of 69% protein 
and 19% fiber and a small quantity of other undefined compositions. These compositions 
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other than the protein may contribute to the benefits of soy protein. As well known, short-
chain fatty acids (SCFA) produced during fermentation of plant fibers in the colon are 
beneficial for preventing colon inflammation and cancer (146). The second aspect is the 
bioactive peptides in the soy protein. At last, specific amino acid compositions may 
contribute to the protective properties of soy protein.  
 One property of any potential bioactive component is that they survive digestion in the 
stomach and in the small intestine, so that they can reach to the colon and exert their 
functions. A newly isolated bioactive peptide, lunasin, may be a candidate. Lunasin has been 
found to be bioavailable in humans. A human study showed that amino acid sequences from 
lunasin were present in plasma samples after soy intake for 30 min and 1 h, whereas no 
peptides from lunasin were detected in plasma samples without soy intake (138).  It has been 
measured that the lunasin in soy protein concentrate was 2.8 g/100g (152). In our study, the 
mice ate about 4g of the diet each day, which contained 1.1g soy protein concentrate, thus the 
daily intake of lunasin for the mice was about 30.8 mg/day. In the in vitro study by De Mejia 
et al. (139), they treated the macrophages with 50μM lunasin and found that the lunasin 
showed a significant anti-inflammatory effect. There is no available data about the dose of 
lunasin in animal study yet, thus we could not compare the dose in our study with other 
publications and confidently decide if the amount of lunasin consumed by the mice would be 
significant. 
Further in vitro or in vivo studies may be conducted to test if lunasin is the bioactive 
component that provides the protective effect observed. Lunasin  is commercially available 
(140) or can be purified from defatted soybean flour (139). To examine its effects, we may 
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treat cell lines with lunasin and measure the gene expression of MUC and TFF by PCR or 
western blotting. For instance, the human intestinal epithelial goblet cells HT29-Cl.16E 
(168), either in their basal state  or treated with interferon-gamma could serve as a model of 
inflammation (169).  Animal colitis models can also be used to investigate the effects of 
lunasin on the mucous barrier. In the animal models, we may also test the digestibility of 
lunasin by quantifying the amount in fecal samples and in the serum to confirm the 
bioavailability of lunasin.  
Both soy and whey are good sources of essential amino acids. The differences of essential 
amino acid profile of casein, soy protein concentrate and whey protein are shown in Table 8. 
The major differences are: soy protein contains significantly more arginine, while whey 
protein has more leucine, lysine and threonine. Whether these differences would be 
associated with their different effects on colon inflammation, or whether specific amino 
acid(s) exhibit anti-inflammatory potential is unknown and further investigations are needed.  
 
2. Investigate the pathways involved in the MUC, TFF gene expression. 
After identifying the bioactive components in the soy protein, further studies may be 
conducted to investigate the pathways that may be involved in the modulation of MUC, TFF 
genes. MUC gene expression has been found to be associated with the MAPK pathway (151). 
We could explore how soy protein affects the factors in this pathway and how these changes 
are eventually related the colon inflammation. There are multiple regulatory pathways for 
TFF, including PI3K/AKT pathway, the Rho-ROCK cascade, COX-2/TXA2-R/Gαq 
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signaling, PLC/PKC, MAP kinase and EGFR signaling (170). We may study how soy protein 
would regulate these pathways and affect the incidence and development of colon 
inflammation.  
 
3. Human feeding study 
Based on the results that soy protein showed protective effects on DSS-induced colitis in the 
present study, we may propose to conduct a human feeding trial to further explore this 
response. Human subjects with IBD could be recruited and randomly assigned to the control 
diet group or soy protein diet group. The protein supplements can be given in a powder form 
and consumed once daily with milk or other beverages (171). The composition of the diets 
would be the same only except for the proteins. Casein would be used as the control protein. 
MUC1-4, TFF1-3, TNF-α concentrations in the serum can be measured in the beginning and 
at the end of the experimental period. Disease activity based on presence of diarrhea, bloody 
stools, abdominal pain and fever would be recorded during the study (172). These parameters 
should be compared between the control group and the soy protein group. The diet effects 
can be analyzed. 
 
In conclusion, our study investigated the protective mechanisms of diets and LGG in a mouse 
model of IBD, with an emphasis on the barrier function. We found that soy protein 
suppressed the DSS-induced inflammatory stimulation of MUC, TFF and TNF-α gene 
expression independently of the probiotic. Whey protein may act as prebiotic to increase 
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microbial survival, but these factors failed to prevent the inflammatory response. Our 
hypothesis that LGG would enhance barrier function was not supported by the data, however, 
we proved that diets differentially affected the barrier function and showed protect effects 
against colitis. Further studies are needed to identify the bioactive components in the soy 
protein that exert the protective effects. The pathways involved in the MUC, TFF gene 
expression should be investigated. In addition, a soy protein human feeding trial would be 
helpful for better understanding the potential of soy protein in IBD prevention and treatment. 
In the present study, we developed a new method for probiotic administration. The methods 
for colonic histological study and quantitative RT-PCR for MUC, TFF genes and LGG-
specific gene were reliable. As alternative, mucin synthesis measurement could be conducted 
to evaluate mucin expression. Fecal bacteria culture method would be another way to 
quantify probiotic recovery from the colon.  
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APPENDIX 
 
Abbreviations: 
DSS: dextran sodium sulfate 
LGG: Lactobacillus rhamnosus GG 
 
 
 
 
 
 
 
 
 
Figure 8  Body weight of mice fed experimental diets 
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Individual F-tests for linear contrasts of means using the SAS GLM
procedure showed:
a significant diet effect (P < 0.05) in DSS groups for days 13-17,
especially between soy and whey diets.
a significant DSS effect (P < 0.05) in casein groups for days 13-17 and
NO significant bacteria effect (P > 0.15) overall for all days.
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Figure 9  Change in body weight over 4-day DSS treatment  
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Table 5A  Effects of diet and bacteria on food consumption (dry weight) before DSS treatment
*
 
 
Food Consumption 
gram/day 
Diets without LGG  Diets with LGG 
Casein Soy Whey  Casein Soy Whey 
n = 16 n = 9 n = 9   n = 13 n = 6 n = 7 
Day 1 2.99 ± 0.09
 
2.57 ± 0.16 2.42 ± 0.10  2.73 ± 0.36 2.52 ± 0.20 2.82 ± 0.10 
Day 2 3.10 ± 0.08
a 
2.87 ± 0.17
ab 
2.58 ± 0.14
b 
 3.05 ± 0.12
ab 
2.82 ± 0.17
ab 
2.88 ± 0.11
ab 
Day 3 3.20 ± 0.10 3.14 ± 0.15 2.80 ± 0.11  3.18 ± 0.09 3.29 ± 0.17 2.92 ± 0.05 
Day 4 2.94 ± 0.14 3.21 ± 0.15 2.76 ± 0.09  2.88 ± 0.10 3.11 ± 0.07 3.03 ± 0.17 
Day 5 2.91 ± 0.10
ab 
3.21 ± 0.09
a 
2.88 ± 0.07
ab 
 2.78 ± 0.10
b 
3.21 ± 0.09
ab 
2.97 ± 0.13
ab 
Day 6 2.77 ± 0.09 3.21 ± 0.09 2.84 ± 0.14  2.92 ± 0.11 3.07 ± 0.20 3.10 ± 0.12 
Day 7 2.66 ± 0.11
b 
3.13 ± 0.12
ab 
2.78 ± 0.15
ab 
  2.86 ± 0.12
ab 
3.36 ± 0.13
a 
2.96 ± 0.18
ab
 
 
 
Table 5B  Effects of DSS, diet and LGG on food consumption (dry weight) during DSS treatment
*
 
 
Food 
Consumption 
gram/day 
Diets without LGG   Diets with LGG 
Casein Soy Whey  Casein Soy Whey 
Control DSS DSS DSS  Control DSS DSS DSS 
n = 6 n = 10 n = 9 n = 9   n = 6 n = 7 n = 6 n = 7 
Day 0, no DSS 2.80 ± 0.18
a 
2.21 ± 0.09
b 
3.04 ± 0.14
a 
2.65 ± 0.18
a 
 2.62 ± 0.11
a 
2.66 ± 0.13
a 
3.00 ± 0.28
a 
2.85 ± 0.14
a
 
Day 1, DSS 2.65 ± 0.22
ab 
2.23 ± 0.08
bc 
2.51 ± 0.21
ab 
1.98 ± 0.31
c 
 2.77 ± 0.10
ac 
2.52 ± 0.22
bc 
2.91 ± 0.06
a 
2.44 ± 0.13
bc 
Day 2, DSS 2.62 ± 0.20
ac 
2.17 ± 0.15
b 
2.74 ± 0.14
ac 
2.16 ± 0.14
b 
 2.78 ± 0.09
ac 
2.49 ± 0.09
bc 
3.01 ± 0.18
a 
2.54 ± 0.07
bc 
Day 3, DSS 2.63 ± 0.24
ad 
2.07 ± 0.12
bc 
2.57 ± 0.15
ad 
1.61 ± 0.21
c 
  2.60 ± 0.11
ad 
1.98 ± 0.14
bc 
2.80 ± 0.15
a 
2.21 ± 0.11
bd 
*values are means ± SE for the n values indicated. 
Means without a common letter differ, P < 0.05. 
 
       
9
1
 
 
 
 
 
* values for ratios are shown as (x 1000)      
± standard error, Significant individual posthoc comparisons are indicated by different italic superscripted letters. 
 
Table 6 Effects of 2% DSS and Diet on selected mouse organ weights and parameters    
                    
mouse parameter 
Diets without LGG   Diets with LGG 
Casein Soy Whey  Casein Soy Whey 
Control DSS DSS DSS  Control DSS DSS DSS 
n = 6 n = 10 n = 9 n = 9   n = 6 n = 7 n = 6 n = 8 
final body weight 19.13 ± 0.80
a
 17.28 ± 0.48
bc
 18.35 ± 0.44
ab
 16.45 ± 0.26
c
 
 
18.34 ± 0.53
ab
 17.95 ± 0.35
ab
 18.18 ± 0.30
ab
 17.43 ± 0.52
bc
 
liver/body weight ratio* 56.1 ± 4.1
a
 50.8 ± 1.9
ab
 46.7 ± 1.2
bc
 50.4 ± 1.4
ab
 
 
47.3 ± 1.7
bc
 49.7 ± 2.2
abd
 43.2 ± 1.8
cd
 52.6 ± 2.9
ab
 
spleen/body weight ratio* 3.05 ± 0.21
ac
 3.22 ± 0.25
ac
 2.85 ± 0.16
ac
 3.63 ± 0.49
ab
 
 
2.71 ± 0.23
c
 3.33 ± 0.26
ac
 2.48 ± 0.19
c
 3.64 ± 0.31
ab
 
cecum/body weight ratio* 9.33 ± 0.74
bc
 8.61 ± 0.82
c
 12.4 ± 0.37
a
 10.8 ± 0.95
ab
(8) 
 
8.50 ± 0.81
c
 8.05 ± 0.76
c
 12.2 ± 0.60
a
 9.01 ± 0.64
bc
(7) 
colon/body weight ratio* 8.86 ± 1.09
d
(5) 10.1 ± 0.36
bcd
 9.76 ± 0.27
bcd
 11.6 ± 0.57
a
 
 
9.18 ± 0.28
cd
 10.3 ± 0.42
ad
 10.7 ± 0.61
ac
 11.0 ± 0.64
ab
 
colon length 6.1 ± 0.2
a
 5.3 ± 0.1
b
 6.2 ± 0.3
a
 5.1 ± 0.1
b
 
 
6.0 ± 0.4
a
 4.9 ± 0.2
b
 6.2 ± 0.2
a
 4.9 ± 0.1
b
 
colon weight/length ratio* 27.3 ± 3.0
c
 33.4 ± 2.0
ac
 29.6 ± 2.4
c
 37.5 ± 2.0
ab
   28.7 ± 2.7
c
 38.0 ± 1.9
ab
 31.5 ± 2.5
ab
 39.3 ± 2.2
a
 
8
5
 
9
2
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Table 7 Protein analysis 
  Casein 
Soy protein 
concentrate Whey protein 
%Protein 95 69 81.5 
% Fat 1.5 3 5.5 
% Lactose 0.2 – 6 
% Ash 2.1 7 3.0 
% Fiber – 19 – 
Calories (kcal/100g) 360 290 394 
Sources: product data sheet from the companies.  
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Table 8  Contents of essential amino acids (EAA) in the casein, soy protein and whey protein 
Amino Acid 
Casein
1
 Soy protein
2
  Whey protein
3
 
Mice 
requirement
4
 
  g EAA/100g of Protein  g EAA/100g diet 
Isoleucine (BCAA) 5.9 4.7 6.0 0.5 
Leucine (BCAA) 9 7.7 10.4 0.7 
Valine (BCAA) 6.9 5 3.6 0.9 
Lysine 7.3 6.5 9.5 0.5 
Methionine 2.9 1.3 2.3 0.1 
Phenylalanine 5.2 5 3.6 0.4 
Threonine 4 3.8 7.5 0.9 
Tryptophan 1.3 1.2 1.1 0.1 
Histidine 2.7 2.6 2.0 0.2 
Arginine 3.7 7.2 2.7 1.5 
BCAA: branch chain amino acid. 
Sources: 
1
MP Biomedicals; 
2
Archer Daniels Midland; 
3
Leprino Foods Dairy Products. 
4
John AM, 
Bell JM. Amino acid requirements of the growing mouse. J. Nutr. 106: 1361-1367, 1976. 
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Probiotic work protocol 
By Debjani Mitra, FSHN 
 
Strain: Lactobacillus rhamnosus GG (LGG) ATCC 53103 
 
Revival of lyophilized culture 
1) Prepare MRS broth tubes and agar plates. 
2) Inoculate 2 MRS broth tubes with lyophilized LGG powder. 
3) Incubate overnight at 37°C. 
4) Streak out on MRS agar plates for purity check and incubate overnight at 37°C. 
5) Pick out single isolated colony and inoculate a broth tube. Incubate overnight at 37°C. 
6) Subculture into second broth tube. Incubate overnight at 37°C. 
Result: Pure and isolated colonies of LGG were seen which were used to prepare pure 
culture suspensions each time. 
 
Growth curve plot 
7) Start Bioscreen run with 50µL culture broth +150 µL MRS broth, incubate for 24h. 
8) Note time taken to reach maximum cell concentration (“T”) from growth curve. 
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Result: Culture reaches stationary phase by 14h. 
 
Estimation of cell concentration. By track plating 
9)  Subculture into 300mL MRS broth in flask. Incubate at 37°C for 24h for cell count 
study. 
10) Centrifuge cell suspension at time, dissolve pellet in 1X PBS (10mL).  
Result: 600mL=11.8g of pellet. 
11) Prepare 8 dilutions of culture broth in PBS (10^2, 10^4, 10^6, 10^7, 10^8, 10^9& 
10^10) 
12) Perform track plating of dilutions from 10^4, 10^6 to 10^10 and find cell 
concentration (cfu’s/ml) . 
Result: Cell concentration= 3*10^10cfu’s/mL or 
    1.5*10^12cfu’s/g 
 
 
 
Viability testing of L. rhamnosus in mice feed 
13) Dissolved cell pellet from step 11 will be used here. 
14) Prepare mice feed in water in beakers: 40%for casein, 110% for soy. 
15) Add 1mL of cell suspension. 
16) Leave beaker at RT for 1-2 hour. 
17) Collect total of 1g of sample from each of the 3 beakers. Samples will be collected 
from at least 3 random locations in the feed. 
18) Sample is dissolved in 100mL PBS and vortexed to mix well (10^2).  Then diluted 
serially in PBS (10^4, 10^6, 10^8, 10^10). 
19) Perform track plating of dilutions from 10^2 to 10^10 and find cell concentration 
(cfu’s/g of feed). 
Result:  
 1h 2h 
 
Soy 1*10^10cfu’s/mL 1.5*10^10cfu’s/mL 
 
Casein 2*10^8cfu’s/mL 1*10^8cfu’s/mL 
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Sample preparation every morning for the probiotic feed 
20) 24h culture broth is centrifuged, pellet collected. 
21) 1g of pellet is transferred aseptically to a tube and 5mL PBS is added to it to get a 
suspension. 
22) Cell counts were taken of the 1g Lactobacillus pellet dissolved in 5mL PBS on 4/2/10 
(mid-way of feeding trial) and showed 6*10^11 cfu’s/ml. 
23) Cell counts taken on 4/8/10 (end of feeding trial) showed 3*10^11 cfu’s/ml. 
 
 
